Quality of Care in Patients with Cirrhosis and Ascites, Hepatic Encephalopathy or Spontaneous Bacterial Peritonitis by Dashputre, Ankur
Duquesne University
Duquesne Scholarship Collection
Electronic Theses and Dissertations
Summer 1-1-2017
Quality of Care in Patients with Cirrhosis and
Ascites, Hepatic Encephalopathy or Spontaneous
Bacterial Peritonitis
Ankur Dashputre
Follow this and additional works at: https://dsc.duq.edu/etd
This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact
phillipsg@duq.edu.
Recommended Citation
Dashputre, A. (2017). Quality of Care in Patients with Cirrhosis and Ascites, Hepatic Encephalopathy or Spontaneous Bacterial
Peritonitis (Master's thesis, Duquesne University). Retrieved from https://dsc.duq.edu/etd/166
  
QUALITY OF CARE IN PATIENTS WITH CIRRHOSIS AND ASCITES, HEPATIC 
ENCEPHALOPATHY OR SPONTANEOUS BACTERIAL PERITONITIS 
 
 
 
 
A Thesis 
Submitted to the School of Pharmacy 
 
 
 
Duquesne University 
 
In partial fulfillment of the requirements for 
the degree of Master of Science 
 
By 
Ankur Dashputre 
 
August 2017 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Ankur Dashputre 
 
2017 
 
 iii 
 
 
 
 
QUALITY OF CARE IN PATIENTS WITH CIRRHOSIS AND ASCITES, HEPATIC  
 
ENCEPHALOPATHY OR SPONTANEOUS BACTERIAL PERITONITIS 
 
 
 
 
 
 
 
By 
 
Ankur Dashputre 
 
Approved June 27, 2017 
 
 
 
________________________________ 
Dr. Jordan R. Covvey 
Assistant Professor of Pharmacy 
Administration 
Duquesne University School of Pharmacy 
(Committee Chair) 
 
 
 
 
________________________________ 
Dr. Branden D. Nemecek 
Assistant Professor of Pharmacy Practice 
Duquesne University School of Pharmacy 
(Committee Member) 
________________________________ 
Dr. Khalid M. Kamal 
Associate Professor of Pharmacy 
Administration 
Duquesne University School of Pharmacy 
(Committee Member) 
 
 
 
 
________________________________ 
Dr. David A. Johnson 
Division Head, Pharmaceutical Sciences 
School of Pharmacy and Graduate School 
of Pharmaceutical Sciences 
 
  
 
 
 iv 
ABSTRACT 
 
QUALITY OF CARE IN PATIENTS WITH CIRRHOSIS AND ASCITES, HEPATIC 
ENCEPHALOPATHY OR SPONTANEOUS BACTERIAL PERITONITIS 
 
 
 
By 
Ankur Dashputre 
August 2017 
 
Thesis supervised by Dr. Jordan R. Covvey 
 
Objective: To analyze concordance with evidence-based clinical care guidelines in real world 
clinical practice in patients with cirrhosis and ascites, hepatic encephalopathy (HE), or 
spontaneous bacterial peritonitis (SBP). 
Methods: A retrospective cohort analysis of the UPMC EMR database (2009-2014) with access 
to full outpatient and limited inpatient data was conducted to identify patients with cirrhosis and 
ascites, HE or SBP. Data regarding patient demographics, clinical characteristics, laboratory 
values and medication utilization were extracted. Analyses included examination of patient 
demographic and clinical characteristics, change in disease severity (via MELDNa scoring) from 
cirrhosis to complication development and outpatient/inpatient healthcare utilization patterns. 
Additionally, concordance with investigator-designed quality care indicators adapted from 
 v 
AASLD guidelines and other sources were assessed to understand real world clinical care. 
Patient- and physician- factors predicting concordance with pharmacotherapy recommendations 
were assessed via the use of logistic regression models. 
Results: The inclusion/exclusion criteria yielded 4,116 patients with liver cirrhosis and 986, 665 
and 148 patients with ascites, HE, and SBP respectively. Concordance with quality indicators 
ranged from 49.83% (recommended medication for HE) to 99.32% (MELD at SBP index). Body 
mass index and physician type were the only predictors that predicted concordance within the 
regression models for the selected indicators (prescription for recommended ascites and HE 
medications). A significant increase in MELDNa was observed from cirrhosis to complication 
index. No differences in healthcare utilization patterns were observed across complications.  
Conclusions: Several opportunities for improvement in quality of care were noted. However, 
factors assessed in this study revealed limited information regarding opportunities to improve 
concordance to clinical guidance.  
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CHAPTER 1: INTRODUCTION 
Liver cirrhosis  
Background 
Cirrhosis is a chronic condition of the liver characterized by the development of scarred 
tissue and subsequent reduced capacity of liver function.1 The liver is involved in multiple 
tasks such as processing of nutrients and their distribution, protein production and regulation, 
drug metabolism, removal of toxic waste, and bile production, which are affected by 
cirrhosis.1,2 Common etiologies of cirrhosis include chronic alcohol abuse, viral infections 
like chronic hepatitis B, C or D, nonalcoholic fatty liver disease, bile duct disease caused by 
backing up of bile into the liver, autoimmune hepatitis and genetic diseases like 
hemochromatosis, Wilson’s disease or glycogen storage disease.1,2 The progressive nature of 
the disease eventually leads to downstream complications such as portal hypertension (PH), 
esophageal varices, ascites, spontaneous bacterial peritonitis (SBP), gastrointestinal bleeding, 
hepatic encephalopathy (HE), renal failure and hepatocellular carcinoma (HCC); all of these 
complications are associated with increased morbidity and mortality.3 The associated 1-year 
mortality is 1%, 3.4%, 20%, 57%, and 67% for compensated cirrhosis with no esophageal 
varices, compensated cirrhosis with varices, decompensated cirrhosis with ascites, 
decompensated cirrhosis with gastrointestinal bleeding, and infections and renal failure, 
respectively.3 Cirrhosis and its complications also impair health-related quality of life 
(HRQoL). Factors such as insomnia, anemia, pruritus, muscle spasms, clinically overt 
fatigue, depression and anxiety, and the presence of complications such as ascites and HE are 
known to affect HRQoL negatively.4-6 
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Pathophysiology 
Damage and destruction of liver tissue resulting from the aforementioned etiologies initiates 
a healing process where healthy liver tissue is counterintuitively replaced by fibrous tissue.7 
This process, called fibrogenesis, leads to liver fibrosis, which can progress to cirrhosis 
depending on the underlying etiology, host factors and environmental factors.7 Cirrhosis is 
accompanied by the distortion of the hepatic vasculature, which involves angiogenesis, or the 
formation of new blood vessels. Cirrhosis can lead to major consequences such as impaired 
hepatocytes, increased intrahepatic resistance and development of HCC.7 The hepatic 
vascular alterations are accompanied by other circulatory abnormalities such as splanchnic 
vasodilation, hypoperfusion of kidneys, water and salt retention, and increased cardiac 
output.7 All these processes result in PH, which further develops into serious complications 
such as ascites, SBP, HE which are associated with higher mortality as discussed 
previously.3,7 Hepatocytes are responsible for carrying out major functions of the body such 
as protein synthesis and storage, carbohydrate metabolism, lipid metabolism, detoxification 
of endogenous and exogenous substances; therefore, hepatocyte impairment affects these 
processes adversely.7,8 Particularly, low albumin levels lead to decrease in oncotic pressure 
allowing leakage of fluid from the interstitial spaces into the peritoneal cavity. The 
combination of low oncotic pressure with PH contributes towards the development of 
ascites.9 As mentioned earlier, hepatocyte dysfunction affects protein production which has 
an effect on creatinine levels (a marker of kidney function) and clotting factors (increasing 
bleeding risk) indicating liver damage. Also, the affected detoxification process may lead to 
increased ammonia levels, which is a contributing factor for HE. 
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Signs, symptoms, diagnosis  
Early stage cirrhosis is typically difficult to diagnose until decompensation occurs as the 
symptoms are not profound.2,3 Initial symptoms experienced by patients are generally non-
specific such as fatigue, weakness, decreased appetite,  weight loss, and nausea.1,2 More 
specific symptoms include nevus araneus (spider angioma, i.e. spider-like blood vessels), 
severe itching (due to elevated bilirubin), abdominal distention due to fluid accumulation 
(ascites), edema in the feet, ankles or legs, and jaundice.1,2 These signs/symptoms can be 
further used as a basis to conduct diagnostic testing for confirmation. 
Diagnostic techniques for cirrhosis are multimodal. A medical/family history provides 
information on potential past exposure to hepatitis viruses (most commonly B or C), as well 
as personal history of alcoholism or genetic and other prognostic factors that may have 
contributed to the disease development.1 Laboratory blood work assessing liver enzyme 
levels for aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) are generally conducted.10 
Elevated levels of AST and ALT are markers of acute liver death. However, as cirrhosis 
progresses, these levels might not always be elevated due to fewer healthy hepatocytes 
releasing these markers when injury occurs.10 Elevated ALP levels suggest blockage of the 
bile ducts, and elevated GGT levels indicate use of alcohol or bile duct diseases.10 Similarly, 
blood protein levels can also be informative, including serum bilirubin (Sbili), serum 
creatinine (SCr), international normalized ratio (INR), and albumin.1,10 SBili tests the 
bilirubin level in blood and elevated levels indicate potential liver disease.1,10 SCr is a 
measure of kidney function and elevated levels indicate abnormal kidney function, though 
this may be misleadingly low in patients with severe cirrhosis due to lack of creatinine 
production by the liver.1,10 INR is a measure of blood clotting ability with elevated levels 
suggesting longer time for blood clotting, resulting from a lack of production of clotting 
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factors by the liver.1,10 Reduced levels of albumin is an indication of liver disease and can 
lead to ascites and abnormal fluid retention in extremities due to a decreased oncotic pressure 
within the circulatory system.1,10 
Sbili, SCr and INR have continued importance to cirrhosis as they are useful indicators to 
calculate the Model for End-Stage Liver Disease (MELD) score.1 The MELD score, 
developed by Kamath et al11 is a measure of the disease severity and is used as a predictor of 
3-month survival to prioritize patients for liver transplantation. The MELD score is calculated 
as follows: 
MELD score = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)) *10 
 
The Organ Procurement and Transplantation Network recently updated the MELD score in 
January 2016, including serum sodium (SNa) in the equation. The MELDNa (updated score) 
is calculated as follows:12  
1. Calculation of the MELD: 
MELD = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)) *10 
2. Calculation of corrected SNa for patients with a serum glucose > 120 mg/dl:13 
Corrected serum sodium (CSNa) = SNa + {0.024*(serum glucose – 100)} 
3. Calculation of the MELDNa using the following formula:14 
MELDNa = MELD + 1.32*(137 – SNa/cSNa) – [0.033*MELD* (137 – SNa/cSNa)] 
 
For both the scores, patients who have undergone dialysis twice in a week and have SCr > 4, 
their SCr value is set at 4.15,16 Any laboratory value < 1 for SCr, Sbili and INR is set at 1.15,16 
Limits for SNa or CSNa values are set between 125 Mmol/L and 137 Mmol/L, with extreme 
values outside of this range adjusted accordingly.17 A higher score corresponds with 
increased severity of disease and mortality. Table 1 provides information on 
MELD/MELDNa score and associated mortality. 
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Table 1. MELD/MELDNa score and associated 3-month mortality15 
 
MELD/MELDNa Score 
Mortality at 3 months 
(% patient expected mortality) 
≤ 9 1.9% 
10-19 6.0% 
20-29 19.6% 
30-39 52.6% 
≥ 40 71.3% 
  
 MELD = Model for End-Stage Liver Disease; MELDNa = Model for End- 
 Stage Liver Disease with Sodium 
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Finally, imaging tests like ultrasound, computerized tomography (CT) scans, and magnetic 
resonance imaging (MRI) are used to study the liver surface, and to determine the presence of 
gastric varices and splenomegaly. Liver biopsy may be utilized to evaluate tissue for 
diagnosing the presence of damage or disease.1 
 
Epidemiology and economic burden 
According to 1999-2010 National Health and Nutrition Examination Survey (NHANES) 
data, the prevalence of liver cirrhosis in the United States (US) is estimated at 633,323 adults 
(0.27%).18 The prevalence by age is bimodal in nature, peaking in the 4th/5th decade of life 
and again after 75 years of age.18 Cirrhosis prevalence is higher in males and in non-Hispanic 
African-Americans, and Mexican-Americans.18 The 2014 National Vital Statistics Reports 
ranks chronic liver disease and cirrhosis as the 12th leading cause of death accounting for 
38,170 deaths (1.5% of all deaths due to all causes) with an age-adjusted death rate of 10.4 
per 100,000.19 The 2010 National Center for Health Statistics reported an estimated 101,000 
short hospital stays associated with chronic liver disease and cirrhosis,20 and an estimated 
635,000 ambulatory visits in patients with cirrhosis in 2009.12  
The economic burden of chronic liver disease and cirrhosis (ICD-9-CM 571.xx) based on 
national hospital inpatient data in 2014 is estimated at approximately $1.5 billion with 
alcoholic cirrhosis of liver (approximately $717 million), cirrhosis of liver without mention 
of alcohol (approximately $457 million), and acute alcoholic hepatitis (approximately $190 
million) contributing to the majority inpatient costs.21 Chronic liver disease and cirrhosis 
accounted for an estimated $2.5 billion in direct costs (drug costs and hospitalizations) and 
$10.6 billion in indirect costs (loss of work productivity) in 2004.22 
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Treatment and guidelines 
Liver cirrhosis does not have a definitive medical cure outside of transplantation, however 
treatments are available to delay disease progression, reduce liver damage and decrease or 
manage complications.2  The American Association for the Study of Liver Diseases 
(AASLD), an organization of scientists and health care professionals with expertise in liver 
diseases, provides evidence-based guidelines with recommendations on preferred approaches 
for diagnostic, therapeutic and preventive aspects of liver disease care with the goal of 
preventing, curing, and managing symptoms of liver disease.23,24 Based on the target liver 
condition, the committee provides specific recommendations to be followed by practitioners 
in their daily practice. The following sections describe selected complications and published 
AASLD management guidelines. 
 
Complications 
As discussed previously, as cirrhosis progresses it can lead to several downstream 
complications, such as esophageal varices, ascites, SBP, gastrointestinal bleeding, HE, renal 
failure and HCC which are associated with 1-year mortality as low as 1% to as high as 
67%.2,3 The development of complication stems from the restricted blood flow from the 
portal vein through the liver which develops into PH, indicated by a hepatic-vein pressure 
gradient (HVPG) of greater than 5 mmHg.3 If left uncontrolled, it develops into clinically 
significant PH (HVPG > 10 mmHg).3 This commonly results in gastroesophageal varices, 
(characterized by dilation of vessels in the esophagus) and increased incidence of HCC.3 In 
particular, a HVPG ≥ 12 mmHg is associated with an increased risk of variceal bleeding 
which can be fatal if not treated urgently.3 PH, sodium retention, changes in circulatory 
oncotic pressure, and splanchnic vasodilation (due to increased nitric oxide production) are 
major contributors to the development of ascites, which is characterized by excess fluid in 
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peritoneal cavity.3 Bacterial infection of this excess peritoneal fluid is called SBP.3 The 
destruction of liver tissue limits the removal of toxic nitrogenous substances from the body 
leading to HE (characterized by altered mental status, confusion, and potentially a coma).25 
Figure 1 presents a simplified outline of the progression of cirrhosis. The focus of present 
study will be on ascites, SBP, and HE and the following sections will provide details of these 
selected complications. 
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Figure 1. Basic schematic presentation of cirrhosis progression  
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Ascites 
Ascites is the most common complication of cirrhosis, and develops as a result of fluid 
accumulation in the peritoneal cavity due to increased portal pressure and changes in 
circulatory oncotic pressure.3,26 As cirrhosis progresses, homeostatic activation of 
vasoconstrictor and anti-natriuretic factors occurs to maintain the effective blood volume.3 
This leads to water and salt retention and eventual fluid accumulation in the peritoneal cavity 
due to increased portal pressure.3 Approximately 50% of patients with cirrhosis who do not 
have HE or variceal hemorrhage (two of the most common other complications) develop 
ascites over a period of 10 years.27 The 1-year and 5-year morality rates associated with 
ascites is 15% and 44%, respectively, and it is the most common reason for complication-
related hospital admissions among cirrhotic patients.27 Based on severity, ascites can be 
classified as mild (not clinically evident, but diagnosable by ultrasound), moderate 
(symmetrical distension of stomach) or severe (noticeable tense distension of stomach).28 
Diagnosis is ascertained by several components. Physical examination focuses on checking 
for bulging abdominal flanks due to accumulation of fluid and may include an ultrasound to 
visualize the fluid.27 Finally, an abdominal paracentesis is utilized to extract abdominal 
ascitic fluid to test for ascitic cell count, levels of albumin and total protein, and for the 
presence of bacteria.27 Patient medical history may also be reviewed for additional cause of 
ascites such as cancer, heart failure, severe renal disease, thyroid disease, and tuberculosis.27 
The goals of ascites management within the AASLD guidelines are to (1) control ascites, (2) 
prevent or relieve ascites symptoms such as dyspnea or abdominal pain and distension, and 
(3) prevent development of SBP and hepatorenal syndrome (HRS).28 AASLD-recommended 
pharmacological therapies include:27 
1) Baclofen: For patients with alcohol dependence to reduce cravings. Administered 
orally at 5 mg three times daily (tid) for 3 days and then titrated to 10 mg tid. 
11 
 
2) Diuretics: To aid in removal of volume overload (primarily ascites) and sodium. First-
line initial combination of oral spironolactone (100 mg) and oral furosemide (40 mg) 
administered in the morning is recommended to achieve rapid natriuresis and to 
maintain normokalemia. Oral spironolactone as single therapy can be used in patients 
with minimal fluid overload. Second-line diuretics include amiloride, triamterene, 
metolazone, and hydrochlorothiazide.  
In patients with ascites, the vasodilatory effect (reduced blood pressure) of nitric oxide is 
mediated by endogenous vasoconstrictors such as vasopressin, angiotensin, and aldosterone.3 
Therefore, AASLD recommends caution/avoidance in the use of angiotensin converting 
enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients with ascites, 
unless there is compelling indication, as these agents counteract diuretics.27 In patients with 
refractory ascites (ascites that does not recede post use of therapeutic paracentesis, sodium 
restriction and diuretics), the risks of beta blockers (BB) should also be carefully considered 
due to their effects on blood pressure and potential for paracentesis-induced circulatory 
dysfunction, though these medications are recommended in PH.27 Lastly, nonsteroidal anti-
inflammatory drugs (NSAID) should be avoided in ascites as they reduce urinary sodium 
excretion and can induce azotemia.27 Lastly, AASLD states that proton pump inhibitors (PPI) 
use has an increased association with SBP (due to changes in bacterial growth in the GI tract) 
and its use should be restricted to indications where necessary.27 
Non-pharmacological strategies for ascites management include restriction of dietary sodium 
to 2000 mg/day in conjunction with diuretics, monitoring urine sodium and fluid restriction 
in patients with hyponatremia.27 In patients with significant edema, weight loss (due to fluid 
loss using diuretics) is recommended.27 On resolution of edema, weight loss (due to fluid 
loss) of 0.5 kg/day is considered reasonable.27 Use of large volume paracentesis is 
recommended for patients with refractory ascites.27 
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Spontaneous bacterial peritonitis  
SBP results from bacterial infection of the ascitic fluid caused by translocation of bacteria-
infected GI tract fluid. In patients with cirrhosis and ascites, there is an increased intestinal 
mucosal permeability, as a result of which bacteria migrate from lymph nodes to blood and 
eventually ascitic fluid.28 Prolonged bacteremia, compromised host defenses, intrahepatic 
shunting of colonized blood and defective bactericidal activity within the ascitic fluid are 
additional factors that may lead to SBP.29 The estimated incidence rate of at least one episode 
of SBP is 10-15% over 1-year in patients with ascites.29 SBP is associated with 20% of in-
hospital mortality among cirrhotic patients.30 In patients surviving SBP hospitalization, the 1-
year and 5-year mortality is approximately 70% and 80%, respectively.29 The recurrence rate 
of SBP is approximately 40-70% within the first year of successfully clearing an episode of 
SBP using antibiotic therapy.29 
SBP is diagnosed by the presence of elevated absolute polymorphonuclear leukocyte (PMN) 
count of ≥ 250 cells/mm3 in the ascitic fluid without an evident intra-abdominal surgically 
treatable source of infection.27 Prevention is initiated with the use of primary (before the first 
episode) and secondary (after the first episode) prophylaxis agents. The goal of prophylaxis is 
to prevent the development of SBP in patients who potentially are at risk, including those 
with ascitic fluid having a total protein < 1.5 g/dl along with impaired renal function (SCr ≥ 
1.2 mg/dl, blood urea nitrogen (BUN) ≥ 25 mg/dl, or SNa ≤ 130 mEq/L) or liver failure.27,30 
It is also recommended to provide prophylaxis for 7-10 days immediately post variceal 
hemorrhage.27 Secondary prophylaxis is always recommended after a prior episode of SBP. 
AASLD recommends the following pharmacological therapies for prophylaxis of SBP: 
1) Primary prophylaxis:  
a. Norfloxacin 400 mg daily or trimethoprim/sulfamethoxazole double-strength 
(800/160 mg) once daily,27 or 
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b. Ceftriaxone 1 gram daily intravenously for 7 days or norfloxacin 400 mg 
twice daily dose for 7 days in patients with cirrhosis and GI hemorrhage.27 
2) Secondary prophylaxis:  
a. Norfloxacin 400 mg daily or trimethoprim/sulfamethoxazole double-strength 
(800/160 mg) once daily,27 or 
b. Ciprofloxacin 500 mg daily may be utilized as an alternative in combination 
with trimethoprim/sulfamethoxazole double strength.27,30 
In patients who develop SBP, AASLD recommends initiation of empiric treatment in patients 
with PMN ≥ 250 cells/mm3 in ascitic fluid in a community-acquired setting who have not 
recently received beta-lactam antibiotics.27 These patients should receive a third-generation 
cephalosporin, preferably IV cefotaxime (2 grams every 8 hours).27 Patients with PMN ≥ 250 
cells/mm3 in ascitic fluid in a nosocomial setting and/or who have recently received beta-
lactam antibiotics should receive antibiotic therapy according to local susceptibility 
patterns.27 Finally, patients with PMN ≤ 250 cells/mm3 in ascitic fluid and signs/symptoms of 
infection (temperature > 100o F or abdominal pain or tenderness) should receive IV 
cefotaxime 2 grams every 8 hours (or a similar cephalosporin)  while awaiting results of 
culture for SBP confirmation.27 
Oral fluoroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin may be used as an 
effective alternative to cefotaxime in patients without vomiting, shock grade II or higher HE, 
or SCr > 3 mg/dl.27 Patients with SCr > 1 mg/dl, BUN > 30 mg/dl or Sbili > 4 mg/dl, should 
also receive albumin 1.5 g/kg of body weight within 6 hours of detection and 1 g/kg on day 3, 
though some clinicians recommend this therapy in all patients being treated for SBP.27 
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Hepatic encephalopathy  
HE is a form of cognitive dysfunction caused by liver insufficiency and/or portosystemic 
shunting (PSS), which eventually manifests into multiple neurological or psychiatric 
abnormalities.31 Scarred liver tissue in cirrhosis is unable to effectively remove ammonia and 
other nitrogenous waste from the body.32 These waste products build up in the body and are 
transported through the blood to the brain adversely affecting neuronal conduction.32 HE is 
associated with a 1-year mortality rate of 64%.3 
HE is described in two forms: overt HE (OHE) and covert HE (CHE).31 Minimal HE (MHE) 
is a type of CHE, with no clinical sign or cognitive changes that might indicate HE which 
might be seen in Grade I HE (another type of MHE) or OHE.31 OHE is characterized by 
varied neurological and psychiatric abnormalities such as lethargy, disorientation, obvious 
personality change, inappropriate behavior, dyspraxia, asterixis, somnolence, confusion, 
bizarre behavior and coma.31 MHE is characterized by normal mental and neurological status 
but may present with a slight delay in coordination.31 Prevalence of OHE is 10-14% at time 
of cirrhosis diagnosis, 16-21% in those with decompensated cirrhosis and 10-50% in patients 
with a transjugular intrahepatic portosystemic shunt.31 Overall, 30-40% of patients with 
cirrhosis develop OHE at some point during their clinical course.31 MHE develops in 20-80% 
of patients with cirrhosis.31 The annual economic burden of HE-attributable hospitalization is 
estimated to range from $1 billion to $7 billion.33 
Diagnostic techniques used for HE in patients with the aforementioned symptoms include 
clinical evaluation for signs suggestive of liver insufficiency and/or PSS in patients with no 
other obvious cause of brain damage.31 Clinical scales (to analyze severity) such as the West 
Haven criteria, as well as neuropsychological or neurophysiological tests (diagnose cognitive 
dysfunction) are also used.31 Use of psychometric or neurophysiological tests such as 
portosystemic encephalopathy syndrome test, critical flicker frequency test, continuous 
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reaction time test, inhibitory control test, Stroop test, SCAN test, electroencephalography 
may provide additional information.31 MRI and CT scans are used in general for first-time 
HE and in case of clinical suspicion of other pathology for brain disease.31 Finally, laboratory 
testing to assess levels of ammonia in the blood is commonly performed.31 However, this 
testing alone does not add any diagnostic, staging or prognostic value. Diagnosis is made 
purely by a combination of symptoms, laboratory values and lack of other possible causes.  
The AASLD provides guidelines for treatment of OHE, however MHE does not have any 
specific guidelines, as its presence is not completely obvious to detection through routine 
clinical examination. The recommendations are as follows:31 
1) Nonabsorbable disaccharides: Lactulose 25 mL every 1-2 hours is recommended until 
at least two soft or loose stools per day are produced and titrated further to maintain 
two or three bowel movements per day. Lactulose works by preventing absorption of 
ammonia within the gut. It is utilized as treatment for OHE, but also for prevention of 
recurrent episodes of HE after the first episode. 
2) Rifaximin: Used as an add-on therapy or alternative therapy to lactulose to prevent 
OHE recurrence in patients who have experienced one or more bouts of OHE while 
on lactulose therapy. 
3) Neomycin: Used as an alternative therapy (last line) as it inhibits glutaminase which 
is responsible for ammonia generation. 
Non-pharmacological treatments for HE include maintaining a daily energy intake of 35-40 
kcal/kg of body weight and daily protein intake of 1.2-1.5 g/kg of body weight/day.31 
 
Problem statement 
Medical care for chronic disease generally involves the use of multiple diagnostic, 
therapeutic and preventive measures. When available, evidence-based guidelines provide a 
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strong framework for practitioners to implement recommendations, which improves the 
quality of care and establishes a strong evidence-based practice. However, it is not 
uncommon to see deviations from these evidence-based guidelines in the real-world practice, 
which adversely impacts clinical care resulting in increased morbidity and mortality.  
AASLD provides evidence-based guidelines for management of ascites, SBP and HE. Use of 
these guidelines by healthcare professionals can provide guidance to quality care, reduce 
disease burden, and decrease associated high mortality rates of the condition.3,5,34 However, 
there is a need to evaluate how well these guidelines are utilized in practice, and what patient- 
and physician- related factors may predict quality of care against clinical guidance. 
Identifying these opportunities for clinical improvement aims to advance disease 
management and patient experience of cirrhosis care. 
 
Hypothesis 
The overall hypothesis of this study is that there is no deviance from AASLD guidelines for 
the selected therapies and quality indicators for quality care in patients with cirrhosis who 
develop ascites, SBP and HE. 
 
Research questions 
1. To describe the demographic and clinical characteristics of patients with liver cirrhosis  
2. To evaluate the change in severity (MELDNa) from cirrhosis to development of ascites, 
SBP and HE 
3. To assess the healthcare utilization patterns of patients with documented ascites, HE 
and SBP  
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4. To assess concordance with selected AASLD guidelines, and quality indicators and 
determine the relationship between patient- and physician- related factors that influence 
concordance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
CHAPTER 2: LITERATURE REVIEW 
The aim of the literature review was to identify studies assessing concordance of clinical care 
to established/recommended care guidelines/quality indicators and quality of care in patients 
with liver cirrhosis and/or ascites, SBP and HE. 
 
Search strategy  
A systematic literature search was conducted using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines, which were modified as 
PubMed was the only database used.35 Peer-reviewed publications were searched using 
PubMed. The search strategy included the keywords and/or combinations extracted from 
PubMed MeSH terms (Refer Table 2). Broader terms used to extract MeSH terms were 
cirrhosis, alcoholic cirrhosis, ascites, peritonitis, hepatic encephalopathy, guideline 
adherence, benchmarking, quality of healthcare, quality assurance, health care, quality 
indicators, health care and standard of care. In addition to extracted keywords, quality of 
care was also used.  
 
Inclusion/exclusion criteria 
The inclusion criteria were as follows: 
1. Studies published between January 2000 – July 2016, 
2. Studies in English language, 
3. Studies conducted in US and non-US based settings 
The exclusion criteria were as follows: 
1. Literature reviews, randomized clinical trials, dissertations, commentaries, editorials, 
summary reports and conference abstracts, 
2. Not focused on quality of care/guideline compliance in cirrhosis ascites, SBP and HE. 
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The PRISMA chart showing search strategy is shown in Figure 2. 
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Table 2. MeSH terms extracted from PubMed for literature search 
 
Cirrhosis Complications 
Quality of care/ 
Guideline adherence 
Cirrhosis 
 Liver cirrhosis(es) 
 Hepatic cirrhosis(es) 
 Liver fibrosis(es) 
 
Alcoholic cirrhosis 
 Alcoholic liver cirrhosis 
 Alcoholic cirrhosis 
 Alcoholic hepatic cirrhosis 
 
Miscellaneous 
 Cirrhosis(es) 
 Cirrhotic 
Ascites 
 Ascites 
 
SBP 
 Peritonitis 
 
HE 
 Hepatic encephalopathy(ies) 
 Portal-systemic 
encephalopathy(ies) 
 Portosystemic 
encephalopathy(ies) 
 Portal systemic 
encephalopathy(ies) 
 Hepatocerebral 
encephalopathy(ies) 
 Hepatic coma(s) 
 Hepatic stupor(s) 
 Fulminant hepatic failure with 
cerebral edema 
Guideline adherence 
 Policy compliance 
 Protocol compliance 
 Institutional adherence 
 
Quality of healthcare 
 Quality improvement(s) 
 
Quality assurance, health care 
 Healthcare quality 
assurance(s) 
 Health care quality 
assurance(s) 
 Healthcare quality 
assessment(s) 
 Health care quality 
assessment(s) 
 
Quality indicators, health care 
 Healthcare quality 
indicator(s) 
 Healthcare global trigger 
tool 
 
Benchmarking 
 Best practice analysis 
 Benchmark 
 Benchmarks 
 Healthcare benchmarking 
 Health care benchmarking 
Standard of Care 
 Standard of care 
 Care standard(s)  
Miscellaneous 
 Quality of care 
 
 
HE: hepatic encephalopathy; SBP: spontaneous bacterial peritonitis 
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Figure 2. Modified PRISMA diagram for literature review 
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 Records screened  
(n=1,329) 
Records excluded 
(n=1,303) 
Full-text articles assessed for eligibility 
(n=26)  
Full-text articles excluded 
(n=14) 
 5 research letters and 
commentaries 
 2 reviews 
 1 abstract 
 3 on cirrhosis but with 
specific focus on 
hepatocellular carcinoma, 
hemorrhage, gastrointestinal 
bleeding 
 1 on validity of quality 
indicators 
 1 on development of quality 
indicators 
 1 article in French 
 
 
 
Studies included in qualitative synthesis  
(n=12) 
Records identified through searching PubMed using 
combination of extracted MeSH terms 
(n=1,329) 
Studies included in qualitative synthesis  
(n=12) MeSH: medical subject headings 
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Table 3. Studies evaluating quality of care, guideline/quality indicator concordance 
 
Study 
(year) 
Country 
Aim 
Cirrhosis/ 
Complication 
Setting Study Sample 
Benchmark/ Quality 
improvement/ Quality 
of care 
Study findings 
US-based 
Sclair SN36 
(2016) 
US 
To study the 
adherence to 
cirrhosis-specific 
QI 
Cirrhosis Retrospective cohort 
study of patients seen at 3 
healthcare facilities 
(Faculty practice: 
University of Miami 
Health System; Safety-
net: Jackson Memorial 
Hospital and VA: Miami 
VA Medical Center) 
between Oct 1 2010 - 
Mar 31 2011 
≥18 years; ICD-9-
CM diagnosis 
cirrhosis (571.2, and 
571.5) 
 
n=242 total with 
n=85 Faculty 
Practice; n=81 Safety 
Net; n=76 VA 
Adherence to 6/41 QI 
developed by Kanwal F 
et al (2010)37 for 
cirrhosis 
Adherence ranges for QI: 
 Faculty practice: 30-66% 
 Safety-net: 25-73% 
 VA: 30-63% 
Tapper EB38 
(2016) 
US 
To study the 
effects of QIm 
protocol on 30-
day readmission 
of patients with 
liver cirrhosis 
HE, SBP  Prospective study at the 
inpatient facility of Beth 
Israel Deaconess Medical 
Center between 2010 - 
2013 
All patients admitted 
to liver unit 
 
n=824 total 
Two phase QIm (hand-
held checklist and 
electronic phase vs usual 
care) targeted at: Use of 
rifaximin for all patients 
with HE; Adjusting 
lactulose dose to mental 
status using the 
Richmond Agitation and 
Sedation Scale; Timely 
administration of correct 
dose of antibiotics and 
albumin; Maximizing 
patients who received 
primary and secondary 
prophylaxis for SBP 
 67.7% of admitted overt HE 
patients had documentation of 
use of rifaximin 
 42% of patients with history or 
index admission of SBP 
received secondary antibiotic 
prophylaxis 
 Checklist and electronic phases 
received 8738 and 8858 20 mL 
of lactulose doses respectively 
(vs 6209 doses in usual care) 
Lim N39 
(2015) 
US 
To study the 
relationship 
between physician 
specialty and 
HE, RA, SBP Retrospective study of 
electronic medical 
records at inpatient visits 
at University of Vermont 
≥18 years; inpatient 
discharge diagnosis 
of ICD-9-CM 571.2, 
571.5 and 571.6 
3 practice-based QM 
each for RA and SBP 
from AASLD 2009/2012 
guidelines. 3 practice-
Quality of care criteria met: 
 RA: 20/39 admissions 
 HE: 56/83 admissions 
 SBP: 11/33 admissions 
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inpatient quality 
of care i.e. 
adherence to 
evidence-based 
specialty society 
practice guidelines 
Medical Center between 
Jun 2009 - Jul 2013 
 
n=247 total 
 
based QM for HE from 
PPACP 
 
 Intensivists-managed patients 
received significantly better 
quality of care 
 Gastroenterology consultation 
was associated with a 
significantly higher adherence 
to quality indicators for HE but 
not for other complications 
Ghaoui R40 
(2015) 
US 
To study the 
impact of 
implementing 
mandatory 
gastroenterologist 
consultation (MC) 
on adherence to 
QI and outcomes 
compared to usual 
care (UC) 
Ascites, HE Comparison of 
prospective cohort with 
MC intervention to 
retrospective review of 
UC managed patients at 
Baystate Medical Center. 
 
UC cohort: Jan 1, 2009 - 
Dec 31, 2009; MC 
cohort: Jun 1, 2011 - Jun 
30, 2012 
≥18 years; patients 
with suspected/ 
established ascites, 
HE 
 
n=303 total with UC 
n=149; MC n=154 
8 and 2 inpatient QI for 
ascites and HE 
respectively developed 
by Kanwal F et al 
(2010)37 
Post implementation of MC 
intervention (vs UC): 
Ascites:  
 82.2% received diagnostic 
paracentesis post admission (vs 
39.9%)  
 75% admissions with known 
portal-hypertension related 
ascites receiving paracentesis 
had ascites cell count checked 
(vs 14.4%,) 
 66.4% with normal renal 
function received proper 
management (vs 30.6%) 
 
HE:  
 85.8% had better documented 
search of etiologies leading to 
HE (vs 53.6%)  
Johnson 
KB41 
(2015) 
US 
To study the 
adherence to 
guidelines for 
reducing the 
albumin dose at 
large-volume 
paracentesis 
(LVP)  
Ascites Retrospective cohort 
study of patients with 
LVPs at Department of 
Radiology, Massachusetts 
General Hospital between 
Jul 1, 2009 - Jan 31, 2014 
Patients with 
gastroenterologist- 
documented cirrhosis 
and have undergone 
LVP at Department 
of Radiology 
 
n=935 total with pre-
guideline (PrG)  
(July 1, 2009 - Jun 
30, 2011): n=288; 
4-point LVP guidelines 
established by 
interdisciplinary group 
of radiologists, 
hepatologists and 
transfusion medicine 
specialist 
PoG group: 36.3% of LVPs 
performed in accordance to 
guidelines 
 
Adherent vs non-adherent: 
 Volume of ascites removed 
was statistically higher (5.6 vs 
5.2; p<0.001) 
 Albumin dose administered 
(g/L of ascites) and cost per 
LVP was significantly lower 
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post-guideline (PoG) 
(Jul 1, 2009 - Jan 31, 
2014): n=647  
(7.4 vs 11.9; p<0.001 and 
$1,824.20 vs $2,107.63; 
p<0.001, respectively) 
Ghaoui R42 
(2014) 
US 
To study 
adherence to QI in 
patients admitted 
with 
decompensated 
cirrhosis 
Ascites, HE Retrospective cohort 
study of patients admitted 
to Baystate Medical 
Center between Jan 1, 
2009 - Dec 31, 2009 
≥18 years; ICD-9-
CM diagnosis of 
571.0-571.9, 572-
572.4 and 576.0 
 
n=149 total 
7 and 2 QI for patient 
with ascites and HE 
respectively developed 
by Kanwal F et al 
(2010)37 
Adherence to QI ranges: 
 Ascites: 14.4-76.9%  
 HE: 53.6-95.4% 
Desai AP43  
(2014) 
US 
To study the effect 
of co-management 
between 
hospitalists and 
hepatologists on 
quality of care and 
adherence to 
management 
guidelines for 
Chronic Liver 
Disease and SBP 
SBP Retrospective chart 
review of patients 
admitted with CLD and 
SBP at University of 
Chicago Medical Center 
between July 1, 2004 - 
June 30, 2010 
≥18 years; 
 
Patients with ICD-9-
CM for peritonitis 
(567.23, 567.0, 
567.21, 567.29, 
567.89, and 567.9) 
and Current 
Procedural 
Terminology code for 
paracentesis (49080)  
 
n=56 total with 
Conventional Model 
group (CM) (July 1, 
2004 - June 30, 
2006): n=26; Co-
management group 
(CoM) (July 1, 2006 - 
June 30, 2010): n=30 
12 evidence-based 
recommended quality of 
care processes for SBP  
 CoM group was found to be 
significantly more adherent to 
5/12 processes as compared to 
CM group  
 Adherence ranged from 17-
100%  
 Quality care provided by CoM 
group was better 
Kanwal F44 
(2012) 
US 
To study quality 
of ascites care 
provided to 
Veterans using 
established QI 
Ascites, SBP Retrospective cohort 
study using records from 
administrative and 
clinical database followed 
by a structured implicit 
review of patient medical 
charts using data from 
Veteran electronic 
Patients with ICD-9-
CM for cirrhosis 
(571.2, 571.5, 571.6) 
or related 
complications (456.0, 
456.1, 456.20, 
456.21, 572.2, 572.3, 
572.4, 572.8, 789.5) 
in inpatient or 
Adherence to 8/41 QI 
developed by Kanwal F 
et al (2010)37 
 Adherence ranged from 22-
89% 
 Quality of ascites care was 
higher in the VA facility with 
academic affiliation compared 
with those without such 
affiliation 
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medical record system 
between 2000 - 2007 
outpatient encounters 
 
n=774 total 
 
Non-US -based 
Le S45 
(2016) 
Australia 
To study effect of 
adherence to 
ascites QI on 
clinical outcomes 
for patients 
hospitalized for 
new onset 
cirrhotic ascites 
Ascites Retrospective cohort 
study of patients seen 
Monash Hospital between 
Jan 2000 - Oct 2012 
≥18 years; ICD-9-
CM diagnosis of 
portal hypertension, 
cirrhosis (571.2, 
571.5, 571.6), other 
ascites), paracentesis, 
and other sequelae of 
chronic liver disease 
(572.8) 
 
 n=302 total 
Adherence to 8/13 QI 
developed by Kanwal F 
et al (2010)37 for ascites 
 Adherence ranged from 70-
92%  
 2 QI were significantly 
associated with lower relative 
risk of 30-day readmission  
 1 QI each was significantly 
associated with lower and 
higher relative risk of 90-day 
mortality 
Thevenot 
T46 
(2013) 
France 
To evaluate 
antibiotic 
prophylaxis 
prescription 
tendencies for 
primary and 
secondary 
prophylaxis of 
SBP 
SBP Prospective national 
survey of hepato-
gastroenterology 
practitioners in general 
hospitals (GH) and 
university hospitals (UH) 
between Nov 2011 - Mar 
2012 
Hepato-
gastroenterologist 
practitioners 
 
n=389 total 
EASL, AASLD  94.8% practitioners prescribed 
secondary prophylaxis for SBP 
(93.5% of GH vs 98.1% of UH 
practitioners)  
 72.3% practitioners used 
antibiotics for primary 
prophylaxis of SBP (70.7% of 
GH vs 76.4% of UH) 
Morando F47 
(2013) 
Italy 
To evaluate 
efficacy and 
financial 
sustainability of 
healthcare model 
in comparison to 
standard care 
Ascites Prospective cohort study 
of outpatients discharged 
from the General Hospital 
of Padova between Jan 
1,2011 - Jun 30, 2011 
≥18 years; 
 
n=100 total with 
care-management 
check-up group n=40 
(Group 1); standard 
care n=60 
(Group 2) 
 
Team of consultant 
hepatologists, nurses and 
clinicians involved in 
providing improved care 
through implementing 
various quality 
improvement initiative  
Group 1 vs Group 2: 
 Reduction of mortality rate in 
patients with responsive ascites 
(24.2%, p<0.05) and those 
with refractory ascites (20.1%, 
p=NS) 
 Significantly lower percentage 
of 30-day emergent 
readmission to the hospital 
(15.4 vs 15.4%; p<0.01) 
 Significantly lower percentage 
of emergency hospitalization 
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during 12-month follow-up 
(46.2 vs 71.2%; p<0.025) 
Gundling 
F48 
(2009) 
Germany 
To study 
adherence to 
nutrition specific 
recommendations 
by 
gastroenterologists  
Cirrhosis  Prospective survey of 
gastroenterologists at 
Bavarian Society of 
Gastroenterology 
between Jul 1, 2007 - Sep 
1, 2007 
Gastroenterologists 
 
n = 239 total 
Questionnaire (in 
addition to 9 nutrition 
specific questions) 
seeking information on 
knowledge of recent 
guidelines on enteral 
nutrition (EN) and 
estimated relevance of 
such guidelines, if such 
guidelines can be 
realizable in daily 
practice and whether 
careful advising by 
professional dieticians is 
meant to be important 
for patients with liver 
cirrhosis 
 56% familiar with guidelines 
on EN in patients with chronic 
liver disease 
 92% believed that evidence-
based guidelines are both 
important and relevant for 
everyday practice  
 84% considered such 
recommendations as realizable 
in daily practice 
 
AASLD: American Association for Study of Liver Diseases; EASL: European Association for Study of the Liver HE: hepatic encephalopathy; ICD-9-CM: International Classification of 
Diseases, Ninth Revision, Clinical Modification; PPCACP: Practice Parameters Committee of the American College of Gastroenterology; RA: refractory ascites; SBP: spontaneous 
bacterial peritonitis; QI: quality indicator; QIm: quality improvement; QM: quality measures; VA: Veterans Affairs  
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Results 
Table 3 provides a summary of the studies regarding complications, setting, study sample, 
benchmark/quality improvement/quality of care criteria and study findings. A total of 12 
articles were identified based on the inclusion/exclusion criteria out of which 8 were 
conducted in the US36,38-44 and 4 were international studies45-48 (1 each in Germany, Italy, 
France and Australia). Ten studies looked at concordance to quality indicators 
(QI)/guidelines whereas two studies focused on quality improvement. Ascites was the most 
common complication studied (7/12 studies, 58.3%), followed by SBP (5/12 studies, 41.7%) 
and HE (4/12 studies, 33.3%).  For the purpose of the review the study findings are 
categorized into two categories: Concordance with QI/guidelines and Quality improvement. 
 
Concordance with QI/guidelines  
Five of the 10 studies on  concordance with QI/guidelines (4 US and 1 in Australia) used QI 
established by Kanwal F et al37 Sclair SN et al36 retrospectively compared the concordance to 
six QI in three hepatology clinics [University of Miami Health System (faculty practice), 
Jackson Memorial Hospital (safety-net hospital), and Miami VA Medical Center VA)] in the 
Miami Health District, USA) for patients with cirrhosis receiving care from faculty at the 
University of Miami. The percentage concordance to QI ranged from 30-66% (safety-net 
hospital), 25-73% (faculty practice) and 39-63% (VA). Patients at the safety-net hospital and 
VA received statistically higher Hepatitis A/B vaccination and hepatocellular carcinoma 
surveillance in comparison to faculty practice patients. However, receipt of screening 
endoscopy and discussions on liver transplant were statistically higher in faculty practice as 
compared to the other two. Multivariate analysis results showed that patients with >10 
hepatologist visits had statistically higher odds of receiving Hepatitis B vaccination and liver 
transplant discussion (OR: 3.31, 95% CI 1.21-9.02; p<0.05 and OR 2.98, 95% CI 1.08-8.17; 
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p<0.05 respectively vs 1-3 hepatologist visits). Females were more likely to receive a 
Hepatitis B vaccination (OR: 2.62, 95% CI 1.17-5.91; p<0.01), and African-American 
patients were less likely to receive liver transplant discussion (OR: 0.36, 95% CI 0.13-1.0; 
p<0.05).  
Ghaoui R et al40 compared concordance to eight QI (for ascites) and two QI (for HE) 
between patients managed by gastroenterologist (prospective) and patients managed by usual 
care (retrospective). In the prospective phase, concordance with QI for ascites ranged from 
60-97.6% and for HE was 85.8-94.7%. For the gastroenterology group in comparison to usual 
care, following QI were better met: (1) ascites: receipt of diagnostic paracentesis for ascites-
related admission (82.2 vs 39.9%; p<0.001), checking for ascites cell count for those 
receiving paracentesis with a known portal hypertension-related ascites admission (75.8 vs 
14.14%; p<0.001), use of sodium restriction and diuretics combination (66.4 vs 30.6%; 
p<0.001) and (2) HE: empirical treatment (95.3 vs 94.7%), and better documentation of 
search for underlying etiologies (85.8% vs 53.6%; p<0.001). In an earlier retrospective study, 
Ghaoui R et al42 looked at concordance with 7 and 2 inpatient QI for ascites and HE, 
respectively. The concordance with ascites QI ranged from 14.4-76.9% and for HE 53.6-
95.4%. Kanwal F et al44 retrospectively identified concordance with QI at the VA for patients 
with ascites and SBP using 8 QI. The concordance with QI ranged from 22.2-82.8%. 
Multivariate regression results showed that patients with higher serum sodium (125-135 
mEq/ml and >135 mEq/ml) had lower odds of receiving recommended care (OR: 0.72, 95% 
CI 0.52-0.99 and 0.58, 95% CI 0.35-0.74 respectively vs serum sodium < 125 mEq/ml); 
patients with albumin ≥ 3 mg/dl had lower odds of receiving recommended care (OR: 0.51, 
95% CI 0.35-0.74) vs albumin ≤ 2.2 mg/dl); patients without comorbidities received 
recommended care compared to patients with comorbidities (Deyo index 0 vs > 3; OR: 2.21, 
95% CI 1.43-3.43); patients who saw a specialist received higher quality of ascites care than 
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those who did not (OR:1.33, 95% CI 1.01-1.74); the VA facility with academic affiliation 
provided better care compared to those without such affiliation (OR:1.73, 95% CI 1.29-2.35).  
Le S et al45 studied the effect of concordance with QI on 30-day readmission and 90-day 
mortality of patients with ascites. Concordance with eight of the selected QI ranged from 70-
92%. Patients who received an abdominal paracentesis within 30-days of ascites diagnosis 
and those receiving abdominal paracentesis during index ascites admission had lower odds of 
30-day readmission (OR: 0.41, 95% CI 0.22-0.41; p=0.004 and OR: 0.57, 95% CI 0.38-0.57; 
p=0.006, respectively). Patients with normal renal function receiving diuretics within 30-days 
of ascites diagnosis had lower odds of 90-day mortality (OR: 0.28, 95% CI 0.10-0.77; 
p=0.01). Interestingly, patients receiving primary prophylaxis (with ascitic fluid protein < 1 
g/dl and serum bilirubin > 2.5 mg/dl) within 3 to 30-days of the test result had higher odds of 
90-day mortality (OR: 2.30, 95% CI 1.05-5.05; p=0.04).  
Lim N et al39 studied the relationship between physician and inpatient quality of care, as 
measured by concordance with evidence-based guidelines (AASLD and Practice Parameters 
Committee of the American College of Gastroenterology) for refractory ascites, SBP and HE. 
Quality of care criteria was met in 20/39 inpatient admissions for refractory ascites; 56/83 
admissions for HE and 11/33 admissions for SBP. A significantly higher proportion of 
intensivist-managed admissions, compared with those managed by hospitalists, met criteria 
for concordance with quality care indicators for HE (100 vs 63%; p=0.03), but not for 
refractory ascites or SBP. Gastroenterology consultation was obtained in a significantly 
higher proportion of admissions that met quality care criteria (68.7% vs 54.0%; p=0.023). 
Among hospitalist-managed admissions, gastroenterology consultation was associated with a 
significantly higher concordance with quality indicators for HE (86.9% vs 52%, p=0.004) 
only. 
Specifically for SBP, not having a timely diagnostic paracentesis was associated with 
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significantly increased median length of hospital stay (5 days vs 13 days; p=0.02). 
Johnson KB et al41 assessed the effect of concordance with 4-point guideline for reducing 
albumin dose at large-volume paracentesis (LVP). Of the total 647 LVPs performed, only 
235 were in concordance with the guidelines. In comparison to the non-concordant LVPs, 
concordant LVPs had a significantly higher volume of ascites removed (5.6 vs 5.2 L; 
p<0.0001); significantly lower amount of albumin dose delivered (7.4 vs 11.9 g/L; p<0.0001) 
and lower cost per LVP ($1,824.20 vs $2,107.63; p<0.0001). 
Desai AP et al43 compared the concordance with12 evidence-based indicators for SBP 
patients treated by co-management model team (hospitalist team and liver consult team) 
versus conventional model team (house staff team and liver consult team). The concordance 
ranged from 17-100% for the co-management model team and 22-100% for the conventional 
model team. The co-management model team provided overall better care and significantly 
better care for 5/12 measures. Co-management group had non-significant longer length of 
stay (11 vs 6 days) and cost of hospital stay ($82,888 vs $41,518). Percentage of readmission 
at 30-days was non-significantly higher for co-managed group (31 vs 17%). However, 
percentage of in-hospital mortality and mortality rate at 30-days was non-significantly lower 
(13 vs 27% and 0 vs 5% respectively). 
Thevenot T et al46 prospectively studied French national prescribing patterns of practitioners 
treating SBP. Results showed that 72.3% prescribed primary prophylaxis for SBP (76.4% 
university hospital based and 70.7% primary hospital based) and 94.8% prescribed secondary 
prophylaxis for SBP (98.1% university hospital based and 93.5% primary hospital based). 
Second-generation quinolones were prescribed majorly for primary and secondary 
prophylaxis. High frequency use (> 75%) of primary prophylaxis was significantly associated 
with high frequency use of secondary prophylaxis (OR: 3.57, 95% CI 1.41-9.09; p=0.007). 
High frequency use of secondary prophylaxis was significantly associated with high 
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frequency use of primary prophylaxis (OR: 2.86, 95% CI 1.16-7.19; p=0.022). Overall, there 
was high concordance with guidelines by the practitioners. 
Gundling F et al48 studied concordance with  European Society for Parenteral and Enteral 
Nutrition (ESPEN) guidelines by gastroenterologists for patients with cirrhosis. Of the 239 
responses, 56% responded that they were familiar with guidelines on enteral nutrition. 92% 
believed that evidence-based guidelines are both important and relevant for everyday practice 
and 84% considered such recommendations as realizable in daily practice. 85% answered that 
careful dietary counseling by professional dieticians would be important for treatment. 42% 
recommended their patients a protein-rich diet containing 1.2-1.5 g/kg body weight/day, 
whereas 15% advised a low-protein diet containing less than 40 g of protein/day or just the 
same amount of protein as recommended in patients without cirrhosis. 45% were aware of the 
optimal daily energy intake of whereas 43% underestimated the amount of required daily 
energy while 11% advised higher energy intake. 
 
Quality Improvement (QIm) 
Tapper EB et al38 performed a prospective study to assess the effect of a QIm protocol on 30-
day readmission for HE. A two-phase (hand-held checklist and electronic) QIm initiative 
targeted at: (1) use of rifaximin for all patients with HE, (2) adjusting lactulose dose to 
mental status using the Richmond Agitation and Sedation Scale (3) timely administration of 
correct dose of antibiotics and albumin, and (4) maximizing patients who received primary 
and secondary prophylaxis for SBP was implemented compared against usual care. Results 
showed that 67.7% of patients admitted with overt HE had documentation of use of 
rifaximin; 42% with history or index admission of SBP received secondary antibiotic 
prophylaxis; checklist and electronic phases received 8,738 and 8,858 20 mL of lactulose 
doses respectively (vs 6,209 doses in usual care). Among patients initially admitted with 
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OHE, the proportion readmitted within 30-days was significantly lower in the electronic 
phase (26.0%) compared with the checklist (44.7%; p<0.001) and control phases (48.9%; 
p=0.002) respectively. The use of rifaximin for patients admitted for overt HE was associated 
with lower odds of 30-day readmission (OR: 0.39, 95% CI 0.16-0.87; p=0.02). Patients with 
SBP who received secondary prophylaxis had lower odds of 30-day readmission (OR: 0.40, 
95% CI 0.21-0.75; p=0.004). There was no significant association for 90-day mortality. 
Patients with OHE who received 6 cups or more of lactulose had lower odds of 30-day 
readmission (OR: 28.8%, 95% CI 5.3-52.7%; p=0.02). 
Morando F et al47 studied the efficacy and financial sustainability of care management group 
(CM) comprising of consultant hepatologists, nurses and clinicians versus standard care (SC) 
for outpatients with ascites. Patients with responsive ascites and refractory ascites in CM 
group had reduced 12-month mortality rate (24.2%; p<0.05 and 20.1%, p=NS. respectively) 
as compared to SC. Patients in CM group had significantly lower percentage of 30-day 
emergent readmission to the hospital (15.4 vs 42.4%; p<0.01) and lower percentage of 
emergency hospitalization during 12-month follow-up (46.2 vs 71.2%; p<0.025) as compared 
to SC. Global costs for CM was significantly lower for as compared to SC ($1,479.19 vs 
$2,816.13; p<0.05). 
 
Gaps in the literature 
Studies focused on assessing concordance with guidelines/QI showed that concordance 
varied and there was no specific trend observed due to the different guidelines/QI being 
assessed.36,39-46,48 Results showed that specialists (hepatologists, gastroenterologists, 
collaborative groups) provided better quality of care and were more concordant with 
guidelines.39,40,43,44,47,48 Better concordance/implementation of QIm was generally associated 
with lower odds of 30-day readmission.38,45,47 However, Desai AP et al43 found higher odds 
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of re-admission associated with quality care. For the outcome of mortality, better 
concordance/implementation of QIm was associated with lower odds of 30-day mortality 
(Desai AP et al43) and of 12-month mortality (Morando F et al47). However, Le S et al45 
found higher odds of 90-mortality. Overall, there was no consistency in the guidelines/QI 
used for assessment, though QI by Kanwal F et al37 were used the most. For US-based 
studies, concordance with evidence-based guidelines such as AASLD was assessed in only 
one study.39 Majority of the studies did not discuss patient-related factors associated with 
guidelines/QI concordance, while physician factors were discussed in few.  
The results of this literature analysis provide sufficient justification for the aims of the 
present analysis to assess the patient- and physician-related factors associated with 
concordance/deviance to AASLD guidelines and selected quality indicators using 
retrospective EMR data. 
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CHAPTER 3: METHODOLOGY 
The main goal was to assess concordance with evidence-based care in real world practice and 
thus EMR was used as the data source, as they provide an in-depth understanding of current 
clinical care. 
 
Data source 
The study design is a retrospective cohort analysis using electronic medical records (EMR) 
from a large academic-based healthcare organization, the University of Pittsburgh Medical 
Center (UPMC). The organization includes more than 20 hospitals and 500 outpatient offices 
providing healthcare across southwestern Pennsylvania. The UPMC network additionally has 
an insurance division, which covers nearly 3 million members.49 
 
UPMC EMR database 
A data extraction was requested from the UPMC Center for Assistance in Research using 
eRecord (CARe), which provides access requests for healthcare data within the UPMC 
network.50 CARe works with researchers to review research protocols, provide programming 
support and access to other resources. The UPMC EMR data held through CARe contains 
both inpatient and outpatient data on patient demographics and clinical characteristics, 
clinical diagnoses, healthcare utilization, laboratory tests and associated results and 
prescribed medications, among other data. In coordination with a UPMC clinician (Dr 
Nemecek, thesis committee member), a data request was created for both Epic (outpatient 
data) and Cerner (inpatient) systems.  
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Data protection 
Data extracted from the UPMC network was based upon an Enterprise Master Person Index 
(EMPI) identification for the organization. This was subsequently converted to a dummy 
patient ID (Code) for the purposes of data manipulation. No patient identifiers were present 
in the data to maintain patient confidentiality. The researchers involved in the study were 
certified by the Collaborative Institutional Training Initiative (CITI). The study was carried in 
compliance with The Health Insurance Portability and Accountability Act of 1996 (HIPAA). 
The study was approved by institutional review boards at both Duquesne University and 
UPMC. 
 
Database structure 
The EMR database extracted by UPMC CARe and provided to the study investigators was 
organized into a relational database structure. Relational databases have different tables, 
which contain multiple rows and columns. Columns represent specific data attributes that are 
stored in the table. For example, the DEMOGRAPHICS table includes columns such as year 
of birth, sex, race etc. Rows represent data that is specific to each observation. For example, 
each row in DEMOGRAPHICS table represents associated information for each patient. A 
primary key, or unique identifier, relates all the tables in the database to each other. The EMR 
database organized from the data extract contained five related tables, with a dummy patient 
ID (Code) serving as the primary key. The five tables in the database are as follows: 
DEMOGRAPHICS, OFFICE VISITS, HOSPITAL VISITS, LABORATORY TESTS, and 
MEDICATIONS. Figure 3 depicts the database structure.
  
3
6
 
          Figure 3. Extracted UPMC EMR database structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient ID 
i.e. Code
(primary key)
DEMOGRAPHICS 
- Year of birth
- Sex
- Race
- Ethnicity
OFFICE VISITS
- Office visit date
- Height
- Weight
- Provider specialty
- Primary diagnosis (ICD-9-CM)
- Other diagnoses (ICD-9-CM)
MEDICATIONS
- Name 
- Ordering date
- Dose
- Dose unit
- Route
- Frequency
- Directions of use 
HOSPITAL VISITS 
- Hospital visit date
- Type of visit (OP, IP, ER)
- Provider specialty
- Diagnosis code (ICD-9-CM) 
- Diagnoses description
LABORATORY TESTS
- Test name
- Result date
- Test value
ER: emergency room; ICD-9-CM: International Classification of Diseases, 
Ninth Revision, Clinical Modification; IP: inpatient visit; OP: outpatient  
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Study sample 
Identification of study sample involved a two-step process:  
Step 1  
Creation of the study sample began with a data extraction by programmers from UPMC 
CARe. This step-involved isolation of patients from the UPMC database based on following 
inclusion criteria: 
1. At least 18 years of age 
2. At least two International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) outpatient visit coding for cirrhosis (571.2, 571.5, 571.6) 
or ascites (789.59), spontaneous bacterial peritonitis (SBP) (567.23) or hepatic 
encephalopathy (HE) (572.2)  
3. Outpatient visits between January 1, 2009 and December 31, 2014 
4. At least 365 days of total EMR activity 
This step yielded an initial cohort size of n=7,824. Detailed data from outpatient and limited 
data from inpatient files were extracted for patients within this cohort and delivered to the 
study investigators. 
 
Step 2  
To suit the specific study goals, a secondary step of data refinement was conducted by the 
investigators and comprised of the following inclusion criteria: 
1. Age between 18 and 90 years 
2. At least one ICD-9-CM coding for alcoholic cirrhosis (571.2) or non-alcoholic 
cirrhosis (571.5) as a primary or secondary diagnostic code at an outpatient visit 
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This step yielded a study sample of n= 4,116, which was further stratified into three groups 
based on the type of cirrhosis coding recorded during patient office visits. As each patient 
had multiple office visits, they were stratified into: 
1. Alcoholic cirrhosis (Alc): ICD-9-CM 571.2 only 
2. Non-alcoholic cirrhosis (N-Alc): ICD-9-CM 571.5 only 
3. Undetermined (Und): ICD-9-CM: 571.2 and 571.5 both  
Complications observed after the first diagnoses of cirrhosis i.e. cirrhosis index (explained 
shortly) were used as a part of the analysis. A total of 986, 665, and 148 patients with ascites, 
HE, and SBP were identified, respectively.  
Sample selection is represented in Figure 4.  
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Figure 4. Patient selection criteria for study cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2 
Outpatient visits between January 1, 2009 and December 31, 2014 (n=7,619) 
 
Patients with at least one ICD-9-CM coding for alcoholic (571.2) or non-alcoholic (571.5) cirrhosis as 
a primary/secondary outpatient visit code (n=5,594) 
Alcoholic cirrhosis  
(ICD-9-CM: 571.2) 
(n=404) 
Nonalcoholic cirrhosis  
(ICD-9-CM: 571.5) 
(n=3,284) 
Undetermined  
(ICD-9-CM: 571.2/571.5) 
(n=428) 
Step 1 Patient sample extracted by CARe using initial inclusion criteria (n=7,824) 
 
Patients with no outpatient visits 
(n=205) 
Patients with no 
primary/secondary 
cirrhosis coding 
(n=2,025) 
Patients with < 365 
days of data 
(n=1,475) 
Patients with data > 365 days of data (n=4,119) 
 
 
Patients < 18 years 
and > 90 years 
(n=3) 
Final cohort meeting inclusion/exclusion criteria (n=4,116) 
 
 
Ascites (n=986) 
HE (n=665) 
SBP (n=148) 
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Description of study variables 
 
Index dates (cirrhosis, complications) 
The cirrhosis index date was defined as the first appearance of a cirrhosis diagnosis ICD-9-
CM of 571.2 or 571.5 as a primary or a secondary diagnosis at an outpatient visit during the 
study timeframe. Similarly, complication index dates were defined as the first appearance of 
an ascites (789.59) or HE (572.2) diagnosis recorded up to 10 diagnoses codes (including 
primary diagnoses) at an outpatient visit during the study timeframe. For SBP (567.23) 
diagnoses recorded up to ten diagnoses codes including primary diagnoses at an inpatient 
visit was used to define index date as this complication is most commonly diagnosed in the 
inpatient setting. Complications with a complication index on or after cirrhosis index were 
used as part of the analysis for this study. Each of these variables is noted in this text as 
cirrhosis index date, ascites index date, HE index date or SBP index date.  
 
Patient demographic variables 
Patient related variables include age, sex, race, and ethnicity. The information was obtained 
from the DEMOGRAPHICS table and obtained from data reported in outpatient records, 
although not directly derived from the OFFICE VISITS table. 
 
Age at cirrhosis/complication index date 
Age at the cirrhosis index date was calculated as the difference between index date and year 
of birth. The variable year of birth was originally available in the DEMOGRAPHICS table. 
Age at cirrhosis index was reported in years and categorized as: 18-40 years, 41-60 years and 
≥ 61 years. Age at the complication index date was calculated as the difference between 
index date and year of birth. The variable year of birth was originally available in the 
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DEMOGRAPHICS table. Age at complication index was reported in years and categorized 
as: 18-40 years, 41-60 years and ≥ 61 years. 
 
Sex 
The variable sex was used as an indicator of sex of the patient. 
 
Race 
The variable was categorized as: Caucasian, African-American, Other (American Indian, 
Chinese, Filipino, Indian, Korean, Other Asian, Other Pacific Islander), and Undetermined 
(not reported). 
 
Ethnicity 
The variable was categorized as: non-Hispanic, Hispanic and Undetermined (not reported). 
 
Patient clinical variables 
Clinical variables included body mass index (BMI) at index date, common co-morbidities, 
Model for End-Stage Liver Disease score/-Na (MELD and MELDNa) score, and Cirrhosis-
specific Comorbidity index (CirCom) score. BMI, common comorbidities, CirCom was 
derived from information available in the OFFICE VISITS table. MELD was derived from 
the LABORATORY TESTS table.  
 
BMI at cirrhosis/complication index date 
BMI at the cirrhosis index date was calculated based on the height and weight reported at the 
cirrhosis index date in the OFFICE VISITS table. Height reported in feet and inches was 
converted to meters and weight reported in pounds was converted to kilograms. BMI was 
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reported as kilograms/meters2 (kg/m2) in the following established categories:51 0-18.5 kg/m2 
(underweight), 18.5-24.9 kg/m2 (normal), 25-29.9 kg/m2 (overweight), ≥ 30 kg/m2 (obese) 
and Undetermined (where BMI could not be determined due to missing height, weight or 
both). Cases where height was not available at the index date, the height recorded at previous 
or following outpatient visit was considered for the calculation. Similarly, BMI at 
complication index date was calculated and reported in following categories: 0-24.9 kg/m2 
(Underweight/Normal), 25-29.9 kg/m2 (overweight), ≥ 30 kg/m2 (obese) and Undetermined 
(where BMI could not be determined due to missing height, weight or both). BMI categories 
at complication index were collapsed due to the smaller sample size of patients within the full 
stratification. 
 
Common co-morbidities 
Presence of comorbidities was based on ICD-9-CM coding from the first visit for the patient 
in the database through three months’ post-cirrhosis index date. Up to ten diagnoses codes 
(ICD-9-CM) including primary diagnoses code were looked up to determine presence of the 
comorbidity. The comorbidities included in this study were based on investigator selection of 
interest and the comorbidities considered by Jepsen et al52 for developing the CirCom score. 
The type of co-morbidities included and associated ICD-9-CM is reported in Table 4. 
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Table 4. Common co-morbidities and their associated ICD-9-CM code 
 
Co-morbidity ICD 9-CM codes 
COPD 
490.xx – 492.xx 
494.xx 
496.xx 
AMI 410.xx 
PAD 443.9 
Epilepsy 345.xx 
Alcohol abuse 305.0x 
Substance use other than alcohol 
304.xx 
305.1x – 305.9x 
Heart failure 428.xx 
Diabetes 250.xx 
Depression 
296.2x – 296.3x 
311.x 
Viral hepatitis 070.xx 
Bipolar 
296.0x 
296.4x – 296.8x 
CKD 585.xx 
Non-metastatic and non-
hematological cancer 
140.xx – 195.xx 
199.xx 
209.xx 
230.xx – 239.xx 
Metastatic cancer 
196.xx  
197.xx 
198.xx 
Hematological cancer 200.xx – 208.xx 
 
  AMI = acute myocardial infarction; CKD = chronic kidney disease;  
 COPD = chronic obstructive pulmonary disease; ICD-9-CM =  
 International Classification of Diseases, Ninth Revision, 
 Clinical Modification; PAD = peripheral artery disease 
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Cirrhosis-specific Comorbidity index  
The CirCom score is a newly developed cirrhosis-specific scoring system, which measures 
the burden and effect of comorbidities on mortality. The CirCom score was developed and 
validated by Jepsen et al52 in three different Danish population-based cohorts. The CirCom 
was replicated in this study and was modified based data availability. Table 5 provides a 
comparison between the method used by Jepsen et al52 and the current study. The CirCom 
score calculation schematic is given in Figure 5. The CirCom score was calculated at the 
cirrhosis index date and was reported in the following established categories: 0, 1+0, 1+1, 
3+0, 3+1, 5+0, 5+1, in line with the original publication.  
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Table 5. Comparison of current study with Jepsen et al52 for CirCom scoring  
 
 Jepsen, et al Current study 
Country Denmark USA 
Aim  Develop and validate CirCom 
score 
Replicate use of CirCom score in US 
population 
Study cohorts and 
sample size 
3 cohorts: 
  
Developmental: Danish patient 
registry cohort (nationwide 
alcoholic or unspecified cirrhosis): 
n= 12,976 
 
Validation cohort 1: Aarhus 
(hospital-based alcoholic 
cirrhosis): n= 419 
 
Validation cohort 2: DANVIR 
(nationwide chronic hepatitis C):  
n=4,656 
1 cohort: 
 
UPMC cohort (hospital-based 
alcoholic and non-alcoholic 
cirrhosis): n= 4,116 
Comorbidities Chronic obstructive pulmonary 
disease; acute myocardial 
infarction; peripheral artery 
disease; epilepsy; substance abuse 
other than alcoholism; heart 
failure; non-metastatic or 
hematological cancer; metastatic 
cancer; chronic kidney disease 
Chronic obstructive pulmonary 
disease; acute myocardial infarction; 
peripheral artery disease; epilepsy; 
substance abuse other than 
alcoholism; heart failure; non-
metastatic or hematological cancer; 
metastatic cancer; chronic kidney 
disease 
Diagnoses codes ICD-10-CM ICD-9-CM 
Healthcare visit type  Outpatient and inpatient visits Outpatient visits 
Comorbidity data 
available for score 
calculation 
5 years of comorbidity data before 
cirrhosis diagnosis 
Variable timelines for comorbidity 
data before cirrhosis index date for 
study years 2009-2014 
Timeline for inclusion 
of comorbidity for 
scoring 
5 years prior to cirrhosis diagnosis Any time prior to cirrhosis index 
date and up to 3 months post-
cirrhosis index date 
Definition of ‘active’  
Status for comorbidity 
Within 7 days prior to cirrhosis 
diagnosis 
Within 7 days prior to cirrhosis 
index date and up to 3 months post-
cirrhosis index date 
 
  CirCom = Cirrhosis-specific Comorbidity index; DANVIR = Danish HCV cohort; ICD-9-CM = International     
Classification of Diseases, Ninth Revision, Clinical Modification; UPMC = University of Pittsburgh Medical Center;  
  US =   United States 
  
 
4
6
 
COPD or  
AMI or  
PAD or  
Epilepsy or  
Substance abuse except 
alcoholism or  
Heart failure or  
Cancer or  
CKD 
CirCom Score 0 
Patient has ‘active’ 
metastatic cancer 
YES 
YES NO 
Patient has at least one of 
the listed comorbidities 
CirCom Score 1+1 
CirCom Score 5+1 CirCom Score 5+0 
YES NO 
CirCom Score 1+0 
‘Active’ AMI and/or 
 
‘Active’ non-metastatic or 
hematological cancer and/or 
 
‘Inactive’ metastatic cancer 
and/or  
 
CKD   
 
NO 
YES 
CirCom Score 3+1 CirCom Score 3+0 
YES NO 
Patient has more than one of 
the listed comorbidities 
NO 
YES NO 
Patient has at least one of 
the listed comorbidities 
Figure 5. CirCom scoring algorithm adapted from Jepsen et al52  
AMI: acute myocardial infarction; 
CKD: chronic kidney disease; 
 COPD: chronic obstructive pulmonary 
disease; PAD: peripheral artery disease 
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Incident/prevalent cases 
Patients who had an index cirrhosis diagnosis within 180 days from first visit recorded in the 
database were classified as prevalent cases whereas patients who had their cirrhosis index 
visit after 180 days from first visit were classified as incident cases. 
 
Model for End-Stage Liver Disease (MELD) 
As mentioned earlier, the MELD score is calculated based on laboratory values from serum 
SCr in mg/dl, Sbili in mg/dl and INR. The formula for calculating MELD is as follows: 
MELD score = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)*10 
 
As mentioned earlier, for patients with SCr > 4, the SCr value was set at 4.0; any laboratory 
value < 1 for SCr, Sbili, and INR was set at 1. Patients who had a diagnosis coding (within 
the first 10 diagnosis codings at an outpatient visit) of ICD-9-CM of V45.11 (renal dialysis 
status) or 585.6 (end-stage renal disease) up to three months prior to and post-cirrhosis index 
date, and complication index date were assumed to have an active dialysis status and their 
SCr value was set at 4. The MELD score was calculated based on laboratory values available 
three months prior, post the cirrhosis index date, and complication index date. To account for 
varied possible values in the wide/broad window period, the numerical mean of the 
laboratory values within the time frame was calculated for each test. The score was reported 
in the following established categories:11,15 ≤ 9, 10-19, 20-29, 30-39 and ≥ 40 and two 
additional categories of Undetermined (score not calculated due to missing values) and 
Missing (scores not calculated due to absence of test).  
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Model for End-Stage Liver Disease with Sodium (MELDNa) 
As discussed earlier, The Organ Procurement and Transplantation Network recently updated 
the MELD score in January 2016, and now includes SNa. The MELDNa (updated score) is 
calculated as follows:12  
1. Calculation of the MELD: 
MELD = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)*10 
2. Calculation of corrected SNa for patients with a serum glucose > 120 mg/dl:13 
Corrected serum sodium (CSNa) = SNa + 0.024*(serum glucose – 100)  
3. Calculation of the MELDNa using the following formula:14 
MELDNa = MELD + 1.32*(137 – SNa/cSNa) – [0.033* O-MELD* (137 – SNa/cSNa)] 
 
Similarly, to MELD, for patients with SCr > 4, the SCr value was set at 4.0; any laboratory 
value < 1 for SCr, Sbili, and INR was set at 1.  Limits for SNa or CSNa values are set 
between 125 Mmol/L and 137 Mmol/L, with extreme values outside of this range adjusted 
accordingly.17 
Patients who had a diagnosis (within the first 10 diagnosis codings at an outpatient visit) of 
ICD-9-CM of V45.11 (renal dialysis status) or 585.6 (end-stage renal disease) up to three 
months prior, and post the cirrhosis index date, and complication index date were assumed to 
have an active dialysis status and their SCr value was set at 4. The MELDNa score was 
calculated based on laboratory values available three months prior, and post the cirrhosis 
index date, and complication index date. To account for varied possible values in the 
wide/broad window period, the numerical mean of the laboratory values within the time 
frame was calculated for each test. The score was reported in the following established 
categories:11,15 ≤ 9, 10-19, 20-29, 30-39 and ≥ 40 and two additional categories of 
Undetermined (score not calculated due to missing values) and Missing (scores not calculated 
due to absence of test).  
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Healthcare utilization variables 
Healthcare utilization was quantified for ascites, SBP and HE using the OFFICE VISITS 
table for office-based visits and HOSPITAL VISITS table for hospital observation, inpatient 
and emergency room hospital visits. Utilization was quantified in two ways: (1) following a 
1-year period from the complication index date, and (2) overall utilization across entire EMR 
record from the complication index date. Patients had to have at least one year of data to be 
included in the utilization metric analyses. Healthcare utilization for each type of service was 
reported as the total number of visits for each complication, mean (± SD) and median (range) 
visits. 
 
Medication utilization variables 
Medication utilization was described for ascites, SBP and HE. Medication-related data was 
extracted from the MEDICATIONS table. The AASLD guidelines recommend 
outpatient/inpatient medications to be prescribed for ascites, SBP and HE.27,31 Data on 
outpatient prescriptions within 30-days post index-date of each complication were analyzed 
to identify following recommended therapies: 
 Ascites: 100 mg daily of spironolactone alone or 100/40 mg daily of spironolactone 
and furosemide in combination.27 The number of patients receiving a prescription, 
mean (± SD) and median (range) dose was reported.  
 SBP: Ciprofloxacin 500 mg daily or combination of ciprofloxacin and double strength 
sulfamethoxazole/trimethoprim (800/160 mg) once daily or 
sulfamethoxazole/trimethoprim (800/160 mg) alone once daily.27 The number of 
patients receiving a prescription was reported. Records were also screened for 
prescription for levofloxacin and moxifloxacin and number of patients receiving each 
was reported. 
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 HE: Lactulose or lactulose and rifaximin combination.31 The number of patients 
receiving a prescription, mean (± SD) and median (range) dose was reported.  
Medication dose strength per unit of time was calculated based on prescribed dose and 
frequency. For example, total daily doses of 100 mg (dose strength /unit of time) were 
calculated as a function of prescribed dose (e.g. 50 mg) and frequency (e.g. twice daily) when 
appropriate. In case of multiple prescriptions in the 30-days post-index period, the 
prescription closest to the index date was reported. 
In addition to recommended medications, records were also analyzed for the following non-
recommended and/or cautioned medication classes and the number of patients receiving that 
class was reported: 
 Ascites: NSAID, ACEI, ARB and BB. PPI as a preventive measure.27  
 HE: Hypnotics (HYP), opioids (OP), benzodiazepines (BZ) and sedating anti-
depressants (AD).53  
 
Concordance with quality care indicators 
Concordance with a set of investigator-designed (adapted from AASLD27 and Kanwal et al37) 
quality indicators (Table 6) was also assessed, based on a review of the guidelines and the 
quality indicators found in the literature review. Quality indicators 1, and 4 to 9 were adapted 
from AASLD and Kanwal et al, and 2 and 3 were investigator-designed as measure of good 
clinical practice. Concordance with each indicator was reported as number and percentage of 
eligible patients, to evaluate the proportion of patients receiving established components of 
quality care.  
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Table 6. Quality care indicators  
 
# Quality indicator Rationale 
1 MELD/MELDNa score available at 
complication index date 
MELD score indicates the severity of the disease and 
prioritization for liver transplant 
2 MELDNa score available at complication 
index date 
MELDNa is recently updated MELD score which 
indicates the severity of the disease and prioritization 
for liver transplant 
3 Weight recorded at each cirrhosis visit Weight loss may occur as the disease progresses, and 
weight gain is utilized as a surrogate measure of ascites 
which requires monitoring 
4 Seen by gastroenterologist at any follow-
up visit post index cirrhosis visit 
As complex disease process, specialist care is good 
clinical practice to ensure appropriate treatment  
5 Primary antibiotic prophylaxis for SBP 
used in qualified patients 
AASLD recommends use for patients with 
cirrhosis/ascites who have ascitic fluid protein < 1.5 
g/dL along with impaired renal function (creatinine ≥ 
1.2, BUN ≥ 25 or serum Na ≤ 130) or liver failure 
(Child score ≥ 9 and bilirubin ≥ 3) 
6 Diuretic therapy within 30-days post-
ascites diagnosis 
AASLD recommends use of spironolactone alone or in 
combination with furosemide for management of 
ascites 
7 Secondary antibiotic prophylaxis within 
30-days post-SBP hospital admission 
AASLD recommends antibiotic treatment for patients 
surviving an initial episode of SBP 
8 Treatment within 30-days post-HE 
diagnosis 
AASLD recommends use of lactulose alone or in 
combination with rifaximin for symptomatic HE 
9 Not on any non-recommended therapies 
   Ascites (NSAID/ACEI/ARB/BB) 
   HE (HYP/BZ/AD/OP) 
 
Not prescribed PPI in ascites 
Classes of medications which either have 
contraindications or precautions for use in patients with 
cirrhosis due to potential for worsening or complication 
of the disease process. Use of PPI in ascites due to an 
observed association with risk for SBP  
 
  # = Number; AASLD = American Association for the Study of Liver Diseases; ACEI = angiotensin converting enzyme 
inhibitor; AD = antidepressant; ARB = angiotensin receptor blocker; BB = beta blocker; BUN = blood urea nitrogen;  
 BZ = benzodiazepine; HE = hepatic encephalopathy; ICD-9-CM = International Classification of Diseases, Ninth Edition, 
Clinical Modification; HYP = hypnotic; MELD = Model of End-Stage Liver Disease; MELDNa = Model of End-Stage Liver 
Disease with sodium; Na = sodium; NSAID = nonsteroidal anti-inflammatory; OP = opioid; PPI = proton pump inhibitor; 
SBP = spontaneous bacterial peritonitis 
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Data management and statistical analysis 
Data management and analysis was performed using Statistical Analysis System 9.4 software 
(SAS Institute; Cary, NC) and Microsoft SQL Server 2012/2014 (Microsoft; Redmond, WA). 
 
Research questions 
 
Research question 1: To describe the demographic and clinical characteristics of patients 
with liver cirrhosis 
Distribution of patient demographic and clinical characteristics at the cirrhosis index date was 
evaluated and their difference was assessed using two-way contingency tables across the 
three extracted cirrhosis etiology categories: alcoholic (Alc), non-alcoholic (N-Alc), and 
undetermined (Und). Frequencies and column percentages were reported for categorical 
variables. A post-hoc Bonferroni correction was used to analyze between-group differences 
for patient characteristics; accordingly, the two-tailed p-value of 0.05 was adjusted to 0.0166 
(p-value/number of comparison groups = 0.05/3). Demographic characteristics included age 
at cirrhosis index date, sex, race and ethnicity. Clinical characteristics included BMI, 
additional diagnoses of biliary cirrhosis, other cirrhosis related etiology, incident or prevalent 
case type, common comorbidities, CirCom score, MELD, and MELDNa. One-way analysis 
of variance (ANOVA) was used to compare across continuous variables. 
 
Research question 2: To evaluate the change in severity (MELDNa) from cirrhosis to 
development of ascites, SBP and HE 
The index dates for cirrhosis and each complication were ascertained. One-way ANOVA 
with a post-hoc Tukey’s test was used to describe the difference between the MELDNa 
scores across the three cirrhosis groups for each complication. The change in MELDNa score 
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for complete cases was assessed using paired t-test, supplemented by the non-parametric 
equivalent sign test. A time window of 6 months between cirrhosis index date and 
complication index date (observed any time after 6 months) was used to assess the change to 
avoid any overlap of MELDNa scores.  
 
Research question 3: To assess the healthcare utilization patterns for ascites, SBP, and HE 
Healthcare utilization was quantified for office-based, hospital observation, inpatient, 
emergency room visits for patients with ascites, HE and SBP. Patients with ≥ 365 days of 
data post-complication index date and more than 1 visit post-complication index were 
included in the analysis. Utilization for each type of service was reported as the total number 
of visits by type of service for each complication and, mean (SD) and median (range) of 
visits. Utilization was quantified in two ways: visits in the first 365 days’ post-complication 
index and total visits, adjusted by follow-up time frame. Follow-up was reported as the mean 
(SD) and median (range) of duration in days. One-way ANOVA with a post-hoc Tukey test 
was used to assess difference in distribution across Alc, N-Alc, and Und. A non-parametric 
Kruskal Wallis test was used to supplement the ANOVA. Independent samples t-test was 
used to assess difference in utilization for office-based, hospital observation, inpatient, 
emergency room visits between ascites and HE.  
 
Research question 4: To assess concordance with selected AASLD guidelines, and quality 
indicators and determine the relationship between patient- and physician- related factors that 
influence concordance 
Concordance with each quality care indicator was reported as number and percentage of 
eligible patients meeting the indicator criteria. Medications prescribed for ascites, HE and 
SBP 30-days post index visit were extracted and the percentage of patients receiving 
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recommended medication, mean (SD), median (range) dose was reported. In addition, non-
recommended medications were also extracted. A multivariable logistic regression was used 
to evaluate the association of demographic and clinical characteristics with the receipt of 
following quality care indicators: 
1. Receipt of diuretic therapy within 30-days post ascites index date (y/n) = β0 + β 
Age(ascites_index) + β Gender + β Race + β BMIascites_index + β MELDNaascites_index + β 
Physician Type + β No. of comorbidities(based on CirCom) + β Cirrhosis type  
 
2. Receipt of treatment within 30-days post-HE index date (y/n) = β0 + β Age(HE_index) + 
β Gender + β Race + β BMIHE_index + β MELDNaHE_index + β Physician Type + β No. 
of comorbidities(based on CirCom) + β Cirrhosis type 
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CHAPTER 4: RESULTS 
 
A total of n = 4,116 patients were included in the final analysis. Depending on the research 
question being addressed, sub-samples were utilized and are reported accordingly.  
 
Research question 1: To describe the demographic and clinical characteristics of 
patients with liver cirrhosis  
 
Sample size 
The total sample size extracted based on the inclusion/exclusion criteria was n = 4,116. The 
demographic and clinical characteristics are listed in Table 7. 
 
Patient demographic variables 
A total of 404 (9.82%) patients had a recorded diagnosis for alcoholic cirrhosis, 3,284 
(79.79%) had a diagnosis for non-alcoholic, and 428 (10.40%) were deemed undetermined. 
The mean age for the sample was 58.33 years (standard deviation [SD]: 10.97 years). A total 
of 40.69% of patients were above 60 years of age whereas patients aged 18-40 years old 
accounted for only 5.03% of the sample. The sample had a slight majority of males (55.68%) 
as compared to females (44.32%). Race was reported for 98.66% of the sample and 
Caucasians (90.33%) formed the majority. Similarly, ethnicity was reported for 97.69% of 
the sample, with non-Hispanics (97.27%) being the most commonly reported ethnicity.  
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Table 7. Distribution of demographic and clinical variables (n=4,116) 
 
Individual 
characteristics 
Alc, n (%) 
(n=404) 
N-Alc, n (%) 
(n=3,284) 
Und, n (%) 
(n=428) 
p-value 
 
Age (at index) 
18-40 
41-60 
> 60 
 
Mean (SD) 
 
26 (6.44) 
282 (69.80) 
96 (23.76) 
 
54.3 (10.06) 
 
157 (4.78) 
1,663 (50.64) 
1,464 (44.58) 
 
59.3 (11.09) 
 
24 (5.61) 
289 (67.52) 
115 (26.87) 
 
54.71 (9.16) 
 
 
<0.0001 
 
<0.0001 § 
Gender 
Male 
Female 
 
271 (67.08) 
133 (32.92) 
 
1,724 (52.50) 
1,560 (47.50) 
 
297 (69.39) 
131 (30.61) 
 
<0.0001 
Race 
Caucasian 
African-American 
Other 
Undetermined 
 
386 (95.54) 
15 (3.71) 
0 
3 (0.74) 
 
2,937 (89.43) 
285 (8.68) 
14 (0.43) 
48 (1.46) 
 
395 (92.29) 
28 (6.54) 
1 (0.23) 
4 (0.93) 
 
 
0.0062 
Ethnicity 
Hispanic 
non-Hispanic 
Undetermined 
 
0 
395 (97.77) 
9 (2.23) 
 
17 (0.52) 
3,190 (97.14) 
77 (2.34) 
 
0 
419 (97.90) 
9 (2.10) 
 
 
0.493 
BMI (at index) 
Underweight 
Normal 
Overweight 
Obese 
Undetermined 
 
8 (1.98) 
106 (26.24) 
135 (33.42) 
138 (34.16) 
17 (4.21) 
 
39 ((1.19) 
596 (18.15) 
906 (27.59) 
1,587 (48.33) 
156 (4.75) 
 
14 (3.27) 
130 (30.37) 
142 (33.18) 
126 (29.44) 
16 (3.74) 
 
 
 
<0.0001 
Incident case 
Yes 
No 
 
273 (67.57) 
131 (32.43) 
 
1,768 (53.84) 
1,516 (46.16) 
 
307 (71.73) 
121 (28.27) 
 
<0.0001 
Other etiology 
Viral hepatitis 
Alcohol abuse 
          
62 (15.35) 
12 (2.97) 
 
991 (30.18) 
47 (1.43) 
 
82 (19.16) 
20 (4.67) 
 
<0.0001 
<0.0001 
Biliary involvement  
Yes 
No 
 
1 (0.25) 
403 (99.75) 
 
77 (2.34) 
3,207 (97.66) 
 
2 (0.47) 
426 (99.53) 
 
0.0010 
Common comorbidities  
Diabetes 
SA w/o alcohol 
COPD 
Depression 
Chronic kidney disease 
Non-met/non-hem cancer 
Heart failure 
Bipolar disorder 
PAD 
Epilepsy 
Hematologic cancer 
Metastatic cancer 
AMI 
      
34 (8.42) 
70 (17.33) 
21 (5.20) 
44 (10.89) 
18 (4.46) 
15 (3.71) 
4 (0.99) 
9 (2.23) 
2 (0.50) 
4 (0.99) 
0 
0 
0 
       
624 (19.00) 
342 (10.41) 
210 (6.39) 
311 (9.47) 
159 (4.84) 
148 (4.51) 
113 (3.44) 
43 (1.31) 
39 (1.19) 
18 (0.55) 
21 (0.64) 
17 (0.52) 
6 (0.18) 
          
34 (7.94) 
65 (15.19) 
13 (3.04) 
32 (7.48) 
13 (3.04) 
10 (2.34) 
3 (0.70) 
6 (1.40) 
2 (0.47) 
3 (0.70) 
1 (0.23) 
1 (0.23) 
0 
 
<0.0001 
<0.0001 
0.017 
0.23 
0.243 
0.095 
0.0004 
0.335 
0.271 †  
0.387 †  
0.208 †  
0.414 †  
1.000 †  
 
  Alc = alcoholic cirrhosis; AMI = acute myocardial infarction; COPD = chronic obstructive pulmonary disease;  
  N-Alc = non-alcoholic cirrhosis, PAD = peripheral artery disease; SA = substance abuse; Und = undetermined.  
  † Fisher’s exact test used; § ANOVA used 
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Age at cirrhosis index, sex and race significantly varied across the three groups.  Patients 
classified with non-alcoholic cirrhosis were older (59.3 [SD: 11.09] years) as compared to 
patients who had alcoholic cirrhosis (54.3 [10.06] years) or undetermined cirrhosis (54.71 
[9.16] years) (p<0.0001).  Patients with alcoholic or undetermined cirrhosis had a higher 
proportion of Caucasian and male patients, compared to those with non-alcoholic, which had 
increased proportions of female and African-American patients. 
 
Patient clinical variables 
BMI at index, incident/prevalent case type, biliary involvement, and presence of 
comorbidities such as COPD, substance abuse other than alcohol, heart failure and diabetes 
significantly varied across the cirrhosis categories. Presence of other cirrhosis etiologies such 
as viral hepatitis and alcohol abuse also showed significant variation of distribution. CirCom, 
MELD and MELDNa distributions could not be compared across the groups due to low 
frequencies (n<5) within the categories present.  
BMI at index date was calculated for 95.41% of the sample based on the availability of height 
and weight variables. From the total sample, 44.97% of the patients were obese (≥30 kg/m2), 
28.74% were overweight (25-29.9 kg/m2), 20.21% had normal BMI (18.5-24.9 kg/m2) and 
1.48% were underweight (0-18.5 kg/m2). While alcoholic and non-alcoholic cirrhosis patients 
had a larger proportion of obese patients, patients classified with undetermined cirrhosis were 
most commonly overweight. A total of 57.05% of the cirrhosis cases were incident cases, 
with alcoholic and undetermined cirrhosis contributing higher proportions than non-
alcoholic. Biliary involvement was very low with only 1.94% of the sample having a 
diagnosis for the same; however, this was significantly more common among those with non-
alcoholic cirrhosis. Etiologies of viral hepatitis and alcohol abuse were observed in 27.97% 
and 1.91% of the total sample, respectively. Diabetes (16.81%) was the most commonly 
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observed comorbidity, which was most commonly seen in non-alcoholic cirrhosis. Substance 
abuse other than alcohol was most common among patients classified with alcoholic and 
undetermined cirrhosis.  
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Table 7 (cont). Distribution of demographic and clinical variables (n=4,116) 
 
Individual 
characteristics 
Alc, n (%) 
(n=404) 
N-Alc, n (%) 
(n=3,284) 
Und, n (%) 
(n=428) 
CirCom 
0 
1+0 
1+1 
3+0 
3+1 
5+0 
5+1 
 
299 (74.01) 
67 (16.58) 
13 (3.22) 
25 (6.19) 
0 
0 
0 
 
2,491 (75.85) 
425 (12.94) 
122 (3.71) 
230 (7.00) 
7 (0.21) 
6 (0.18) 
3 (0.09) 
 
335 (78.27) 
62 (14.49) 
11 (2.57) 
19 (4.44) 
0 
0 
1 (0.23) 
MELD (at index) 
≤ 9 
10-19 
20-29 
30-39 
≥ 40 
Undetermined 
Missing 
 
90 (22.28) 
166 (41.09) 
50 (12.38) 
7 (1.73) 
0 
66 (16.34) 
25 (6.19) 
 
1,081 (32.92) 
1,257 (38.28) 
244 (7.43) 
15 (0.46) 
1 (0.03) 
539 (16.41) 
147 (4.48) 
 
81 (18.93) 
240 (56.07) 
47 (10.98) 
10 (2.34) 
0 
35 (8.18) 
15 (3.50) 
MELDNa (at index) 
≤ 9 
10-19 
20-29 
30-39 
≥ 40 
Undetermined 
Missing 
 
56 (13.86) 
131 (32.43) 
62 (15.35) 
11 (2.72) 
0 
119 (29.46) 
25 (6.19) 
 
770 (23.45) 
1,096 (33.37) 
309 (9.41) 
21 (0.64) 
1 (0.03) 
940 (28.62) 
147 (4.48) 
 
51 (11.92) 
196 (45.79) 
64 (14.95) 
12 (2.80) 
0 
90 (21.03) 
15 (3.50) 
 
  MELD = Model for End-Stage Liver disease; MELDNa = Model for End-Stage Liver disease  
with Sodium; Missing =score not calculated due to absence of test; Undetermined = score not  
calculated due to missing values 
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CirCom score based on comorbidities recorded from first visit in the database to three 
months’ post cirrhosis index was calculated for the extracted sample. Seventy-six percent of 
the patients had a CirCom score of 0 and 13.45% had a score of 1+0, reflecting that 89.37% 
of the sample had a lower comorbidity burden and associated mortality. Despite an inclusion 
period of 3 months pre- and post-index date, MELDNa could not be calculated for 32.45% 
(27.91% undetermined due to missing values for test; 4.54% missing due to absence of test) 
of the sample. For those with available laboratory results, 34.46 % of the patients had a 
MELDNa score between 10-19, and the mean MELDNa score for the entire sample was 
13.59 (SD: 5.84). Similarly, for MELD, 20.10% (15.56% undetermined due to missing values 
for test; 4.54% missing due to absence of test) of the sample did not have a score, 40.40% of 
the sample had score between 10 and 19 and the mean MELD score for the sample was 12.47 
(5.27). 
Patients with alcoholic and undetermined cirrhosis had a higher proportion of patients in 
MELDNa categories of 20-29 and 30-39 compared to those with non-alcoholic cirrhosis, 
which had increased proportions of patients with MELDNa ≤ 9. Patients with undetermined 
cirrhosis had a higher proportion of patients with MELDNa of 10-19 compared to both 
alcoholic and non-alcoholic cirrhosis. No variation was observed for the CirCom score. 
 
Research question 2: To evaluate the change in severity (MELDNa) from cirrhosis to 
development of ascites, SBP and HE 
 
Sample size 
Ascites, HE and SBP were observed in a total of 986 (23.96%), 665 (16.16%) and 148 
(3.60%) patients in the sample, respectively.  
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Distribution and changes in MELDNa  
Of the total patients for ascites, HE and SBP, MELDNa scores were available for 805 
(81.64%), 538 (80.90%), and 145 (97.97%) patients, respectively (Table 8). For patients with 
ascites, the mean MELDNa score was significantly higher for undetermined cirrhosis as 
compared to non-alcoholic cirrhosis (p=0.0003), but not for patients classified with alcoholic 
cirrhosis. Similarly, for patients with HE, the mean MELDNa score was significantly higher 
for undetermined cirrhosis and alcoholic cirrhosis compared to patients classified with non-
alcoholic cirrhosis (p<0.0001). For SBP patients, mean MELDNa was significantly higher for 
patients classified with alcoholic cirrhosis as compared to non-alcoholic and undetermined 
cirrhosis (p=0.0146).  
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Table 8. Distribution of complications and mean MELDNa score 
 
Complication Alc (n=404) N-Alc (n=3,284) Und (n=428) 
p-value 
(ANOVA) 
Ascites (n=805) 
n (%) 
Mean MELDNa (SD) 
 
 
95 (23.51) 
17.90 (6.46) 
 
 
542 (16.50) 
16.15 (5.79) 
 
 
168 (39.25) 
18.04 (6.38) 
 
0.0003* 
HE (n=538) 
n (%) 
Mean MELDNa (SD) 
 
 
55 (13.61) 
18.40 (6.34) 
 
 
377 (11.47) 
15.91 (5.89) 
 
 
106 (24.76) 
18.63 (6.61) 
 
< 0.0001* 
SBP (n=145) 
n (%) 
Mean MELDNa (SD) 
 
 
16 (3.96) 
25.88 (6.99) 
 
 
96 (2.51) 
21.45 (5.71) 
 
 
33 (7.71) 
20.72 (6.30) 
 
0.0146* 
   
  Alc = alcoholic cirrhosis; ANOVA= Analysis of Variance; HE = hepatic encephalopathy; MELDNa = Model for 
  End-stage Liver Disease with Sodium; N-Alc = non-alcoholic cirrhosis; SBP = spontaneous bacterial peritonitis;  
 SD = standard deviation; Und = undetermined cirrhosis 
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When assessing changes in mean MELDNa from cirrhosis index date to complication index 
date for complete cases, there was a statistically significant increase in the mean MELDNa 
from cirrhosis index date to each complication index date observed any time after 6 months 
post cirrhosis index (Table 9). The mean change for MELDNa was highest for SBP patients, 
followed by ascites and HE.  
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Table 9. Changes in mean MELDNa from cirrhosis index to ascites, HE, and SBP index 
 
Index 
Sample 
size 
Mean MELDNa at 
index (SD) 
Mean difference 
(SD) 
t statistic p-value 
Cirrhosis 
220 
13.59 (4.54) 
3.455 (5.808) -8.823 < 0.0001* 
Ascites 17.04 (6.36) 
Cirrhosis 
211 
14.23 (5.22) 
2.213 (5.880) -5.467 < 0.0001* 
HE 16.44 (6.03) 
Cirrhosis 
69 
15.81 (6.12) 
5.783 (7.040) -6.823 < 0.0001* 
SBP 21.59 (5.80) 
 
HE = hepatic encephalopathy; MELDNa = Model for End-stage Liver Disease with Sodium; SBP = spontaneous  
bacterial peritonitis; SD = standard deviation 
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Similar results were found when assessing median MELDNa from cirrhosis index date to 
each complication index date observed any time after 6 months’ post cirrhosis index (Table 
10). Patients with SBP had the highest median MELDNa at 21 (compared to 15 at cirrhosis 
index), while patients with ascites and HE had median MELDNa of 16 (compared to 13 at 
cirrhosis index) (all changes p<0.0001). 
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Table 10. Changes in median MELDNa from cirrhosis index to ascites, HE, and SBP index 
Index 
Sample 
size 
Median MELDNa 
at index (range) 
p-value 
Cirrhosis 
220 
13 (6-33) 
< 0.0001* 
Ascites 16 (7-36) 
Cirrhosis 
211 
13 (6-34) 
< 0.0001* 
HE 16 (6-36) 
Cirrhosis 
69 
15 (7-32) 
< 0.0001* 
SBP 21 (9-36) 
 
  HE = hepatic encephalopathy; MELDNa = Model for End-stage Liver Disease  
 with Sodium; SBP = spontaneous bacterial peritonitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
Research question 3: To assess the healthcare utilization patterns for ascites, SBP and 
HE 
 
Sample size 
Ascites, HE and SBP were observed in a total of 986 (23.96%), 665 (16.16%) and 148 
(3.60%) patients respectively.  
 
Office-based utilization – 1-year follow-up  
A total of 347 (35.91%) patients with ascites had utilization data available for 1-year follow-
up from index for office-based visits (Table 11). Overall, patients with ascites had 1,161 
visits with mean utilization of 3.34 (SD: 3.10) visits in the 1-year follow-up. The non-
alcoholic cirrhosis group had highest numerical utilization, but there were no significant 
differences seen among cirrhosis groups, via either the ANOVA or Kruskal-Wallis tests for 
means and medians, respectively. A total of 205 (30.82%) patients with HE had utilization 
data available for 1-year follow-up for office-based visits. Overall, patients with HE had 615 
visits with mean utilization of 3.00 (1.41) visits in the 1-year follow-up. The undetermined 
cirrhosis group had the highest utilization, but ultimately no significant difference was 
observed among the cirrhosis groups. A total of 5 (3.55%) SBP patients had visits in a 1-year 
period from their index hospitalization. They had overall 13 visits with mean utilization of 
2.60 (0.54) with median (range) of 3 (2-3). An independent samples t-test comparing overall 
utilization for ascites and HE showed that there was no significant difference in utilization 
between the two complications (p=0.074). 
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Table 11. Office-based visit utilization during 1-year post-ascites, HE, and SBP index 
 
Complication Stratification Visits, n Mean (SD) 
p-value, 
ANOVA 
KW 
Median 
(range) 
Ascites 
Overall (n=347) 1,161 3.34 (3.10) - 3 (2-54) 
Alc (n=51) 164 3.21 (1.28) 
0.9207 
0.8078 
3 (2-7) 
Non-Alc (n=212) 720 3.39 (3.78) 3 (2-54) 
Und (n=84) 277 3.29 (1.61) 3 (2-9) 
HE 
Overall (n=205) 615 3.00 (1.41) - 3 (2-14) 
Alco (n=19) 58 3.05 (1.12) 
0.6605 
0.3424 
3 (2-6) 
Non-Alc (n=144) 424 2.94 (1.46) 2 (2-14) 
Und (n=42) 133 3.16 (1.35) 3 (2-8) 
SBP Overall (n=5) 13 2.60 (0.54) - 3 (2-3) 
  
   ANOVA = Analysis of Variance; Alc = alcoholic cirrhosis; HE = hepatic encephalopathy; SBP = spontaneous  
  bacterial peritonitis; KW = Kruskal Wallis; Non-Alc = non-alcoholic cirrhosis; Und = undetermined cirrhosis 
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Office-based utilization – overall follow-up  
A total of 437 (44.32%) patients with ascites had utilization data available for overall follow-
up from index for office-based visits (Table 12). Overall, patients with ascites had 2,163 
visits with mean utilization of 4.94 (4.32) visits across 1,085 days of follow-up, 
corresponding to 1.66 visits/year. The undetermined cirrhosis group had highest utilization, 
but no significant difference in utilization was seen between the three cirrhosis groups. A 
total of 277 (41.65%) patients with HE had utilization data available for overall follow-up 
from index for office-based visits. Overall, patients with HE had 1,257 visits with mean 
utilization was 4.53 (2.81) visits over 1,049 days of follow-up, corresponding to 1.58 
visits/year. The undetermined cirrhosis group had most utilization, but no significant 
differences were seen in comparison to other cirrhosis groups. A total of 10 (6.71%) SBP 
patients had data available for overall follow-up from their index hospitalization with a total 
of 35 visits and a mean of 3.50 (1.17) visits over 1,070 days of follow-up, at 1.19 visits/year. 
An independent samples t-test comparing overall utilization for ascites and HE showed that 
there was no significant difference in utilization between the two complications (p=0.1237).  
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Table 12. Office-based visit utilization overall post-ascites, HE, and SBP index 
 
Complication Stratification 
Visits, 
n 
Mean 
(SD), 
Mean/year 
 
p-value,  
ANOVA 
KW 
Median 
(range), 
Median/ 
year 
Follow-up in 
days,  
mean (SD) 
Median 
Ascites  
Overall (n=437) 2,163 
4.97 (4.32) 
1.66 
- 
4 (2-57) 
1.5 
1,084.75 (531.97) 
974 
Alc (n=63) 300 
4.76 (2.95) 
1.5 
0.657 
0.223 
4 (2-15) 
1.38 
1,157.68 (565.35) 
1,054 
Non-Alc (n=269) 1,308 
4.86 (4.76) 
1.68 
4 (2-57) 
1.56 
1,058.16 (534.24) 
933 
Und (n=105) 555 
5.28 (3.79) 
1.74 
4 (2-22) 
1.39 
1,109 (504.69) 
1,049 
HE  
Overall (n=277) 1,257 
4.53 (2.81) 
1.58 
- 
4 (2-17) 
1.55 
1,049.14 (510.52) 
943 
Alc (n=26) 115 
4.42 (2.19) 
1.40 
0.200 
0.099 
4 (2-10) 
1.33 
1151.62 (543.07) 
1,098 
Non-Alc (n=200) 878 
4.43 (2.80) 
1.60 
4 (2-17) 
1.62 
1,010.63 (499.66) 
898 
Und (n=51) 264 
5.17 (3.07) 
1.64 
5 (2-16) 
1.69 
1,147.94 (525.55) 
1,081 
SBP  Overall (n=10) 35 
3.50 (1.17) 
1.19 
- 
3 (2-5) 
1.12 
1,070 (570.52) 
975 
 
ANOVA = Analysis of Variance; Alc = alcoholic cirrhosis; HE = hepatic encephalopathy; SBP = spontaneous bacterial 
peritonitis; KW = Kruskal Wallis; Non-Alc = Non-alcoholic cirrhosis; Und = Undetermined cirrhosis 
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Hospital Observation/emergency utilization – 1-year follow-up  
A total of 26 (2.63%) patients with ascites had utilization data available for 1-year follow-up 
from index for hospital observation visits with a total of 73 visits and overall mean utilization 
of 2.80 (SD: 1.09) visits (Table 13). A total of 5 (0.75%) patients with HE had utilization 
data available for 1-year follow-up for hospital observation visits with a total of 15 visits and 
overall mean utilization of 3.00 (1.73) visits. A total of 16 (1.62%) patients with ascites had 
utilization data available for 1-year follow-up from index for emergency visits. Overall 
utilization was 62 visits with mean of 3.87 (3.18) visits.  For HE, 5 (0.75%) patients had 
utilization data available with a total of 12 visits and mean utilization of 2.40 (0.89) visits. 
ANOVA and Kruskal-Wallis tests were not conducted on hospital observation or emergency 
visits due to the small sample size, and no data for either utilization type was observed for 
SBP patients.  
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Table 13. Hospital observation/emergency visit utilization during 1-year post-ascites and HE 
index 
 
Health service type, 
Complication 
Visits, n Mean (SD) Median (range) 
Hospital observation 
Ascites (n=26) 73 2.80 (1.09) 2.5 (2-6) 
HE (n=5) 15 3.00 (1.73) 2 (2-6) 
Emergency visits 
Ascites (n=16) 62 3.87 (3.18) 2 (2-13) 
HE (n=5) 12 2.40 (0.89) 2 (2-4) 
   
  HE = hepatic encephalopathy; SD = standard deviation 
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Hospital observation/emergency utilization – overall follow-up  
A total of 44 (4.46%) patients with ascites had utilization data available for overall follow-up 
from index for hospital observation visits (Table 14). Overall utilization was 146 visits with 
mean utilization of 3.31 (3.26) visits over 1,164 days follow-up, corresponding to 1.04 
visits/year. For 10 (1.50%) patients with HE with available data, total utilization was 46 visits 
with mean utilization of 4.60 (5.56) visits over 1,220 days, at 1.38 visits/year. A total of 24 
(3.60%) patients with ascites had utilization data available for overall follow-up from index 
for emergency visits, with total utilization of 99 and mean utilization of 4.12 (4.22) over 845 
days, at 1.78 visits/year. A total of 6 (0.90%) patients with HE had available data, with 
overall utilization of 22 visits and mean utilization of 3.66 (2.25) over 938 days follow-up, 
corresponding to 1.42 visits/year. ANOVA and Kruskal-Wallis tests were not conducted on 
hospital observation or emergency visits due to the small sample size. No hospital 
observation visits were observed for SBP patients, while 2 (1.34%) patients had emergency 
visits for overall follow-up.  
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Table 14. Hospital observation/emergency visit utilization overall post-ascites and HE index 
 
Health service type, 
Complication 
Visits, n 
Mean (SD), 
Mean/year 
Median (range), 
Median/year 
Follow-up in days 
Mean (SD) 
Median 
Hospital observation 
Ascites (n=44) 146 
3.31 (3.26) 
1.03 
2 (2-22) 
0.61 
1,163.73 (541.53) 
1,178 
HE (n=10) 46 
4.60 (5.56) 
1.38 
2.5 (2-20) 
0.76 
1,219.90 (592.77) 
1,208 
Emergency visits 
Ascites (n=24) 99 
4.12 (4.22) 
1.78 
2 (2-20) 
1.14 
844.79 (479.56) 
645 
HE (n=6) 22 
3.66 (2.25) 
1.42 
2.5 (2-7) 
1.14 
937.50 (532.84) 
798.50 
 
 HE = hepatic encephalopathy; SD = standard deviation 
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Inpatient utilization – - year follow-up  
A total of 131 (13.28%) patients with ascites had utilization data available for 1-year follow-
up from index for inpatient visits with a total of 575 visits at a mean (SD) of 4.39 (3.34) visits 
(Table 15).  The alcoholic cirrhosis group (n=14) had highest numerical utilization, but 
results for ANOVA and Kruskal-Wallis showed that there was no significant difference in 
utilization between the three groups. A total of 67 (10.07%) patients with HE had utilization 
data available with overall 235 visits and mean of 3.50 (2.02) visits. The undetermined 
cirrhosis group (n=16) group had most utilization, with the Kruskal-Wallis demonstrating a 
significant difference in utilization. Independent samples t-test comparison between inpatient 
visits for ascites and HE showed that ascites patients had a significantly higher number of 
inpatient visits as compared to HE patients (p=0.0213).  A total of 35 (23.48%) SBP patients 
had inpatient visits in a 1-year period from their index hospitalization with total 77 visits and 
mean of 2.20 (0.47) visits. 
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Table 15. Inpatient visit utilization during 1-year post-ascites, HE, and SBP index 
Complication Stratification Visits, n Mean (SD) 
Median 
(range) 
p-value, 
ANOVA 
KW 
Ascites 
Overall (n=131) 575 4.39 (3.34) 3 (2-21)  
Alcoholic (n=14) 69 4.92 (4.95) 3 (2-21) 
0.5710 
0.8648 
Non-Alc (n=84) 349 4.16 (2.76) 3 (2-15) 
Und (n=33) 157 4.75 (3.91) 4 (2-21) 
HE 
Overall (n=67) 235 3.50 (2.02) 3 (2 -12) 
0.1072 
0.0139* 
Alcoholic (n=13) 41 3.15 (2.79) 2 (2-12) 
Non-Alc (n=38) 123 3.23 (1.60) 3 (2-9) 
Und (n=16) 71 4.43 (2.06) 4 (2-9) 
SBP  Overall (n=35) 77 2.20 (0.47) 2 (2-4) - 
 
  Alc = alcoholic cirrhosis; ANOVA = Analysis of Variance; HE = hepatic encephalopathy; KW = Kruskal  
 Wallis; Non-Alc = non-alcoholic cirrhosis; SBP = spontaneous bacterial Peritonitis; Und = undetermined  
 cirrhosis 
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Inpatient utilization – overall follow-up  
A total of 160 (16.22%) patients with ascites had utilization data available for overall follow-
up from index for inpatient visits with overall 926 visits and mean (SD) of 5.78 (4.72) over 
1,006 days follow-up, corresponding to 2.1 visits/year (Table 16). The undetermined 
cirrhosis group (n=38) group had most utilization, but no significant difference was detected. 
A total of 87 (13.08%) patients with HE had utilization data available for overall follow-up 
with total 414 visits at mean of 4.75 (4.09) visits over 913 days, at 1.90 visits/year. The 
undetermined cirrhosis group (n=20) had the highest, albeit not significantly different, 
utilization among groups. A total of 47 (31.54%) SBP patients had data available for overall 
follow-up from their index hospitalization for inpatient visits with a total of 131 visits at 2.78 
(1.45) visits over 1,072 days, for a total of 0.95 visits/year.  
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Table 16. Inpatient visit utilization overall post-ascites, HE, and SBP index 
 
Complication Stratification 
Visits, 
n 
Mean (SD), 
Mean/year 
Median 
(range), 
Median/ 
year 
p-value, 
ANOVA 
KW 
Follow-up in 
days, 
Mean (SD) 
Median 
Ascites  
Overall (n=160) 926 
5.78 (4.72) 
2.1 
4 (2-33) 
1.61 
- 
1,005.95 (487.96) 
907 
Alcoholic (n=18) 104 
5.77 (5.42) 
2.04 
4 (2-24) 
1.65 
0.4412 
0.2660 
1,031.67 (540.74) 
885.50 
Non-Alc (n=104) 570 
5.48 (4.18) 
1.92 
4 (2-25) 
1.46 
1,039 (501.81) 
1,000 
Und (n=38) 252 
6.63 (5.71) 
2.68 
4 (2-33) 
1.62 
903.31 (416.72) 
799.50 
HE 
Overall (n=87) 414 
4.75 (4.09) 
1.90 
3 (2-27) 
1.46 
- 
913.48 (467.58) 
750 
Alcoholic (n=13) 62 
4.76 (5.38) 
1.45 
2 (2-19) 
0.63 
0.2057 
0.1261 
1,201.62 (572.47) 
1,155 
Non-Alc (n=54) 229 
4.24 (2.84) 
1.73 
3 (2-15) 
1.41 
895.33 (429.80) 
777.50 
Und (n=20) 123 
6.15 (5.65) 
2.9 
4 (2-27) 
2.41 
775.20 (435.28) 
605.50 
SBP  Overall (n=47) 131 
2.78 (1.45) 
0.95 
2 (2-7) 
0.74 
- 
1,072.36 (501.18) 
988 
 
Alc = alcoholic cirrhosis; ANOVA = Analysis of Variance; HE = hepatic encephalopathy; KW = Kruskal Wallis;  
Non-Alc = non-alcoholic; cirrhosis; SBP = spontaneous bacterial peritonitis; Und = undetermined cirrhosis 
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Research question 4: To assess concordance with selected AASLD guidelines, and 
quality indicators and determine the relationship between patient- and physician- 
related factors that influence concordance 
 
Sample size 
Ascites, HE and SBP were observed in a total of 986 (23.96%), 665 (16.16%) and 148 
(3.60%) patients, respectively. 
 
Concordance with clinical care guidelines – ascites  
Medication data was available for 892 (90.46%) patients with ascites. Of these, 514 (57.62%) 
received recommended therapy of spironolactone alone or in combination with furosemide 
within 30-days of index visit. Out of the 514 on recommended therapy, 118 (22.96%) 
received spironolactone alone with a mean dose (SD) of 85.27 mg (50.49 mg). The remaining 
396 (77.04%) received combination therapy with spironolactone/furosemide at a mean dosing 
ratio of spironolactone to furosemide of 90.75 mg: 43.91 mg.  A total of 284 (31.83%) of the 
892 patients were receiving medications that would potentially require caution in prescribing 
in this population, most commonly via the use of BB. Two-hundred and thirty-four patients 
(26.23%) had a prescription for PPI. Table 17 describes the prescription pattern for ascites. 
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Table 17. Medication prescription patterns for patients with ascites 
 
Medication Metric 
Prescribed therapies (n=514) 
Spironolactone/furosemide 
Yes, n (%) 
Mean dosing ratio (SD), mg 
       Median dosing ratio (range), mg 
 
Spironolactone alone 
Yes, n (%) 
Mean (SD) dose/day, mg 
Median dose/day, mg 
 
 
396 (77.04) 
90.75 (48.49) / 43.91 (30.59) 
100 (25-300) / 40 (10-240) 
 
 
118 (22.96) 
85.27 (50.49) 
100 (12.5-300) 
Non-recommended/cautioned therapies (n=892)  
NSAIDS* 
Beta-blockers**  
ACEI*** 
ARB**** 
 
65 (7.29) 
230 (25.78) 
26 (2.91) 
18 (2.02) 
Preventive for SBP (n=892) 
PPI***** 
 
234 (26.23%) 
 
  * includes aspirin, ibuprofen, naproxen, diclofenac, etodolac, meloxicam;  
  ** includes propranolol, nadolol, carvedilol, labetalol, atenolol, bisoprolol-hydrochlorothiazide,  
  metoprolol succinate-hydrochlorothiazide, metoprolol succinate, metoprolol tartrate; 
  *** includes benazepril, enalapril maleate, lisinopril, lisinopril-hydrochlorothiazide, quinapril, quinapril- 
  hydrochlorothiazide, ramipril;  
  **** includes valsartan, azilsartan, medoxomil-chlorthalidone, irbesartan, olmesartan, olmesartan- 
  hydrochlorothiazide; 
  ***** includes omeprazole, esomeprazole, dexlansoprazole, lansoprazole, rabeprazole, pantoprazole 
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Concordance with clinical care guidelines – hepatic encephalopathy 
 
 
Medication data was available for 606 (91.12%) patients with HE. Of these, 302 (49.83%) 
received recommended therapy of lactulose alone or in combination with rifaximin within 
30-days of index visit. A total of 199 (65.90%) received lactulose alone with a mean dose 
(SD) of 73.08 ml (46.48 ml). The remaining 103 (34.10%) received combination of lactulose 
and rifaximin within 30-days of index visit. A total of 173 (28.55%) patients received non-
recommended medications such as HYP, BZ, AD, OP. Table 18 describes the prescription 
pattern for HE. 
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Table 18. Medication prescription patterns for patients with HE 
 
Medication Metric 
Prescribed therapies (n=302) 
Lactulose  
Yes, n (%) 
Mean (SD) dose, mL 
Median (range) dose, mL 
 
Lactulose/rifaximin 
 
 
199 (65.90) 
73.08 (46.48) 
60 (10-240) 
 
103 (34.10) 
Non-recommended/cautioned therapies (n=606) 
Opioids*  
Hypnotics**  
Benzodiazepines*** 
Antidepressants **** 
 
124 (20.46) 
12 (1.98) 
45 (7.43) 
32 (5.28) 
 
  * includes morphine, codeine, tramadol, hydrocodone, oxycodone, oxymorphone, hydromorphone, 
  fentanyl, methadone;  
  ** includes zolpidem;  
  *** includes diazepam, lorazepam, temazepam, clonazepam, alprazolam; 
  **** includes trazodone, amitriptyline, doxepin, nortriptyline, mirtazapine 
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Concordance with clinical care guidelines – spontaneous bacterial peritonitis  
 
 
Medication data was available for 105 (70.94%) patients with SBP. Of these, 57 (54.29%) 
received recommended secondary antibiotic prophylaxis of ciprofloxacin, 
sulfamethoxazole/trimethoprim, moxifloxacin, norfloxacin or combination of ciprofloxacin 
and sulfamethoxazole/trimethoprim within 30-days of index hospitalization. A total of 33 
(57.89%) patients received some dosage of ciprofloxacin, while 20 (35.08%) received dose 
combinations of sulfamethoxazole/trimethoprim. Table 19 describes the prescription pattern 
for ascites. 
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Table 19. Medication prescription patterns for patients with SBP 
 
Medication Metric 
Prescribed therapies (n=57) 
Norfloxacin 400 mg daily 
 
1 (1.75) 
 
Ciprofloxacin 
     500 mg weekly 
     500 mg daily 
     750 mg weekly 
     750 mg three times weekly      
     1000 mg daily 
     1500 mg daily 
 
 
1 (1.75) 
6 (10.52) 
19 (33.33) 
1 (1.75) 
4 (7.01) 
2 (3.50) 
 
Moxifloxacin 400 mg daily 
 
1 (1.75) 
 
Sulfamethoxazole/trimethoprim  
       400/80 mg daily  
       400/80 mg three times weekly 
       800/160 mg daily 
 
 
3 (5.26) 
7 (12.28) 
10 (17.54) 
 
Ciprofloxacin and sulfamethoxazole/trimethoprim 
       750 mg weekly + 800/160 mg daily 
       750 mg weekly + 400/80 mg three times weekly 
 
1 (1.75) 
1 (1.75) 
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Concordance with clinical quality care parameters  
 
Varied concordance rates were observed across each investigator-assigned quality care 
parameter (Table 20). Concordance ranged from 49.83% for indicator 8 (recommended HE 
therapy) to 99.32% for indicator 1 (MELD for SBP). MELD/MELDNa scores were available 
for almost all SBP patients at index (MELD: 99.32%; MELDNa: 97.97%), followed by 
ascites (MELD: 89.45%; MELDNa: 81.64%) and HE (MELD: 88.87%; MELDNa: 80.90%).  
Concordance with recommended therapy was highest for patients with ascites (57.62%), 
followed by SBP (54.29%) and finally lowest for HE (49.83%). Non-recommended 
medications were not prescribed to 71.45% and 68.16% of HE and ascites patients, 
respectively. PPI was not prescribed to 73.77% of the eligible patients with ascites. 
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Table 20. Concordance with quality indicators 
 
Number Indicator (Eligible n) n (%)  
1 
MELD score available at complication index date  
   Ascites (n=986) 
   SBP (n=148)  
   HE (n=665) 
 
882 (89.45) 
147 (99.32) 
591 (88.87) 
2 
MELDNa score available at complication index date  
   Ascites (n=986) 
   SBP (n=148)  
   HE (n=665)  
 
805 (81.64) 
145 (97.97) 
538 (80.90) 
3 Weight recorded at each visit for cirrhosis (n=4,116) 3,280 (79.69) 
4 
Seen by gastroenterologist at least once for all follow-up visit post index 
cirrhosis visit (n=3,444) 
2,870 (83.33) 
5 Primary prophylaxis for SBP used in qualified patients (n=33) 20 (60.61)  
6 Diuretic therapy within 30-days post-ascites diagnosis (n=892) 514 (57.62) 
7 
Secondary antibiotic prophylaxis within 30-days post-SBP hospital 
discharge (n=105) 
57 (54.29) 
8 Treatment within 30-days post-HE diagnosis (n=606) 302 (49.83) 
9 
Not on any contraindicated/non-recommended therapies 
Ascites (n=892) 
HE (n=606) 
 
Not prescribed PPI in ascites (n=892) 
 
 
608 (68.16) 
433 (71.45) 
 
658 (73.77) 
 
  HE = hepatic encephalopathy; MELD = Model for End-Stage Liver Disease; MELDNa = Model for End-Stage Liver     
Disease with Sodium; SBP = spontaneous bacterial peritonitis 
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Patient- and physician-related factors influencing concordance – recommended diuretics 
within 30-days of ascites index date 
 
The results of standard multivariable logistic regression are shown in Table 21, with a total 
of 712 patients included in the logistic regression model. No issues of multicollinearity were 
identified, with all variance inflation factors < 5. Overweight patients had significantly 
lower odds (OR: 0.559; 95% CI: 0.375-0.833) of receiving recommended diuretic therapy 
as compared to patients who were underweight or had normal BMI. Non-gastroenterologist 
or non-primary care physicians had significantly lower odds of prescribing the 
recommended diuretic therapy as compared to primary care physicians (OR: 0.283; 95% CI: 
0.134-0.598). MELDNa categories were collapsed to ≤ 9, 10-19 and ≥ 20 owing to the 
sample size and distribution of scores.  
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Table 21. Predictors of recommended diuretics within 30-days of ascites index date 
 
Parameter Reference B SE 
Wald 
Chi-Square 
Pr >  
ChiSq 
OR (95% CI) 
Intercept  0.8089 0.5303 2.3264 0.1272  
Age at ascites index 
  40-60 
  ≥ 61 
18-40 
 
-0.3339 
-0.5996 
 
0.3775 
0.3872 
 
0.7824 
2.3984 
 
0.3764 
0.1215 
 
0.716 (0.342 - 1.501) 
0.549 (0.257 - 1.173) 
Gender 
  Male 
Female 
 
0.00227 
 
0.1620 
 
0.0002 
 
0.9888 
 
1.002 (0.730 - 1.37) 
Race 
  Other* 
Caucasian 
 
-0.1509 
 
0.3056 
 
0.2439 
 
0.6214 
 
0.860 (0.472 - 1.565)  
BMI at ascites index 
  Overweight 
  Obese 
Underweight/ 
Normal 
 
-0.5813 
-0.0997 
 
0.2036 
0.1994 
 
8.1509 
0.2501 
 
0.0043* 
0.6170 
 
0.559 (0.375 - 0.833) 
0.905 (0.612 - 1.338) 
MELDNa at ascites 
index 
  10-19 
  ≥ 20 
 
≤ 9  
 
 
0.0769 
-0.1055 
 
 
0.2605 
0.2836 
 
 
0.0871 
0.1383 
 
 
0.7679 
0.7099 
 
 
1.080 (0.548 - 1.800) 
0.900 (0.516 - 1.569) 
Physician Type 
  Gastroenterologist 
  Other 
PCP 
 
-0.00692 
-1.2625 
 
0.2034 
0.3817 
 
0.0012 
10.9399 
 
0.9729 
0.0009* 
 
0.993 (0.667 - 1.480) 
0.283 (0.134 - 0.598)   
No. of comorbidities 
  1 
  > 2 
0 
 
-0.0665 
-0.0611 
 
0.1930 
0.3356 
 
0.1188 
0.0331 
 
0.7303 
0.8556 
 
0.936 (0.641 - 1.366) 
0.941 (0.487 - 1.816) 
Type of cirrhosis 
  Non-Alcoholic 
  Undetermined 
Alcoholic 
 
0.3193 
0.2940 
 
0.2498 
0.2824 
 
1.6337 
1.0838 
 
0.2012 
0.2979 
 
1.376 (0.843 - 2.246) 
1.342 (0.771 - 2.334)  
 
Logistic regression modelled for predictors of concordance with ascites therapy 30-day post index (n = 712) 
Global null hypothesis for model, Likelihood Ratio test X2 =28.9577; Pr > ChiSq = 0.0106 
B = parameter estimate, BMI = body mass index; CI = confidence interval; MELDNa = Model for End-Stage Liver Disease 
with Sodium; OR = odds ratio; PCP = primary care physician; SE = standard error 
* Race Other = African-Americans + Others 
Number of comorbidities were calculated based on the presence of conditions specified by CirCom  
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Patient- and physician-related factors influencing concordance – recommended HE therapy 
within 30-days of HE index 
 
The results of standard multivariable logistic regression are shown in Table 22. A total of 
472 patients were analyzed by the model. No issues of multicollinearity were identified, with 
all variance inflation factors < 5. The model indicated that obese patients had significantly 
lower odds (OR: 0.431; 95% CI: 0.261-0.714) of receiving recommended HE therapy as 
compared to patients with underweight or normal BMI. Non-gastroenterologist or non-
primary care physicians had significantly lower odds of prescribing the recommended HE 
therapy as compared to primary care physicians (OR: 0.266; 95% CI: 0.087-0.813). 
MELDNa categories were collapsed to ≤ 9, 10-19 and ≥ 20 owing to the sample size and 
distribution of scores.  
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Table 22. Predictors of recommended therapy within 30-days of HE index date 
 
Parameter Reference B SE 
Wald 
Chi-Square 
Pr >  
ChiSq 
OR (95% CI) 
Intercept  0.0317 0.6476 0.0024 0.9610  
Age at HE index 
  41-60 
  ≥ 61  
18-40 
 
0.5491 
0.6190 
 
0.4564 
0.4631 
 
1.4479 
1.7862 
 
0.2289 
0.1814 
 
1.732 (0.708 - 4.236) 
1.857 (0.749 - 4.603) 
Gender 
  Male 
Female 
 
0.1412 
 
0.1973 
 
0.5121 
 
0.4742 
 
1.152 (0.782 - 1.695) 
Race 
 African-American 
Caucasian 
 
-0.3357 
 
0.4167 
 
0.6489 
 
0.4205 
 
0.715 (0.316 - 1.618) 
BMI at HE index 
  Overweight 
  Obese 
Under-
weight/ 
Normal 
 
-0.1761 
-0.8406 
 
0.2603 
0.2571 
 
0.4578 
10.6923 
 
0.4987 
0.0011* 
 
0.839 (0.503 - 1.397) 
0.431 (0.261 - 0.714) 
MELDNa at HE 
index 
  10-19 
  ≥ 20  
≤ 9  
 
 
-0.1804 
-0.3371 
 
 
0.3173 
0.3502 
 
 
0.3232 
0.9265 
 
 
0.5697 
0.3358 
 
 
0.835 (0.448 - 1.555) 
0.714 (0.359 - 1.418) 
Physician Type 
  Gastroenterologist 
  Other 
PCP 
 
-0.2289 
-1.3241 
 
0.2454 
0.5702 
 
0.8698 
5.3934 
 
0.3510 
0.0202* 
 
0.795 (0.492 - 1.287) 
0.266 (0.087 - 0.813) 
No. of 
comorbidities 
  1 
  > 2 
0 
 
 
-0.1906 
-0.2082 
 
 
0.2323 
0.3716 
 
 
0.6727 
0.3139 
 
 
0.4121 
0.5753 
 
 
0.826 (0.524 - 1.303) 
0.812 (0.392 - 1.682) 
Type of cirrhosis 
  Non-alcoholic 
  Undetermined 
Alcoholic 
 
0.4395 
-0.1279 
 
0.3290 
0.3746 
 
1.7845 
0.1166 
 
0.1816 
0.7327 
 
1.552 (0.814 - 2.957) 
0.880 (0.422 - 1.834) 
 
Logistic regression modelled for predictors of concordance with HE therapy 30-day post index (n = 472) 
Global null hypothesis for model, Likelihood Ratio test X2 =27.4656; Pr > ChiSq = 0.0167 
B = parameter estimate, BMI = body mass index; CI = confidence interval; HE = hepatic encephalopathy; MELDNa = 
Model for End-Stage Liver Disease with Sodium; OR = odds ratio; PCP = primary care physician, SE = standard error  
Number of comorbidities were calculated based on the presence of conditions specified by CirCom  
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CHAPTER 5: DISCUSSION 
 
This chapter includes discussion of the study results, limitations of the analysis, and finally, 
implications and opportunities for future research. 
 
Liver cirrhosis and its complications are known to be associated with considerable mortality 
and morbidity,3 and the prevalence of cirrhosis remains underestimated.18 Though no cure 
exists, cirrhosis can be pharmacologically managed to delay the development of further 
complications. The AASLD guidelines provide evidence-based practice recommendations for 
diagnostic, therapeutic and preventive aspects of care for liver diseases. Derived from these 
guidelines, clinicians and researchers have established indicators to measure achievement of 
evidence-based delivery of quality care, such as those established by Kanwal et al37 A 
number of subsequent studies have assessed concordance with quality care indicators for 
ascites, HE and SBP as well as the impact of concordance on clinical outcomes.39,40,42-46,48 
Patient- and/or physician-related factors predicting concordance with quality indicators were 
assessed in only one study, which focused on ascites only.44  Thus, this study was conducted 
to assess concordance with quality care using selected AASLD recommendations, quality 
indicators by Kanwal et al37 and investigator developed quality indicators for ascites, HE and 
SBP and assess patient- and physician-related factors predicting concordance with quality 
care. The primary goal was to assess the concordance with established evidence-based quality 
care parameters and/or guidelines and to further assess patient- and physician- factors that 
influence concordance. Additionally, the study also described other preliminary analyses to 
give a more complete picture of the care of patients with cirrhosis. 
The first research question was to describe the sample characteristics that might potentially 
affect concordance with and receipt of quality care, eventually influencing generalizability of 
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the results. Describing the demographic and clinical factors provided a survey of the patient 
sample being analyzed and the potential applicability to other populations. The second 
research question was to assess the change in disease severity via MELDNa across 
development of different complications. Understanding the progression of cirrhosis with 
clinical complications may provide a better idea of how to effectively manage patients. The 
third research question focused on measuring office-based, inpatient, hospital observation 
and emergency utilization for each complication. Receipt of poor quality of care can lead to 
higher healthcare utilization and an overall increased burden on the patient. Healthcare 
utilization patterns are thus an outcome of quality of care. This study however did not assess 
utilization patterns as an outcome or predictor of quality care, but rather to understand the 
burden of utilization for these complications. Finally, the final research questions focus 
specifically on quality of care achievement and patient- and physician-related predictors. 
The first objective of this study was to describe the overall sample based on the patient 
demographic and clinical characteristics. Surprisingly, in this study 80% of the sample had a 
diagnosis of non-alcoholic cirrhosis (cirrhosis without the mention of alcohol), whereas only 
10% of the sample was diagnosed with alcoholic cirrhosis. Chronic alcoholism is the leading 
cause of cirrhosis in the US and higher prevalence of alcoholic cirrhosis would be expected in 
this sample.2 The National Institute of Alcohol Abuse and Alcoholism reports that of all 
cirrhosis deaths (for 2013), 47.9% were attributable to alcohol.54 The Allegheny County 
Health Survey reports 35% of the surveyed Allegheny County adults (≥ 18 years) self-
reported binge drinking (defined as 5 or more drinks for males and 4 or more drinks for 
females in the past 30-days) for the year 2015-2016, a statistic which fairly remains 
unchanged when compared to year 2002 (34%) and years 2009-2010 (33%).55 Similarly, the 
Substance Abuse and Mental Health Services Administration report on National Survey on 
Drug Use and Health revealed that 25.6% of the surveyed adults (≥ 12 years) in the 
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Pittsburgh Metropolitan Statistical Area self-reported binge drinking, as compared to the 
national statistic of 23.2% (2005-2010).56   Though binge drinking does not necessarily 
indicate alcoholism and further development of alcoholic cirrhosis, based on these statistics it 
would be safe to assume that our sample had significantly low number of alcoholic cirrhosis 
patients than expected. Ten percent of the patients were classified as having ‘Undetermined 
cirrhosis’ (ICD-9-CM diagnosis for both alcoholic and non-alcoholic cirrhosis). Alcoholic 
cirrhosis and non-alcoholic cirrhosis are two distinct exclusive classifications for identifying 
the type of cirrhosis. It is surprising that 10% of the sample had a primary/secondary 
diagnosis for both. This finding highlights the need for careful use of diagnosis codes to 
classify patients based on underlying etiology as it may influence the nature of management 
of such misclassified patients. 
The estimates of age (mean age of 58.33 years), predominance of male gender (55.68%), 
high BMI (30.5) and high prevalence of comorbid diabetes (16.81%) found in our study, 
though not similar to the US national estimates for cirrhosis provided by Scaglione et al using 
NHANES, were seen in a higher proportion for the mentioned characteristics.18 Scaglione et 
al18 indicated a higher prevalence in non-Hispanic African-Americans (29.3%) and Mexican-
Americans (34.3%). Our study was composed with a majority Caucasian population 
(90.33%), which can be attributable to the demographics of the region of Pittsburgh (64.8% 
non-Hispanic white, 2010 Census Bureau) served by the UPMC network.57 Based on age 
distribution, male majority, number of patients with history of alcohol abuse and substance 
abuse other than alcohol, it can be hypothesized that patients classified with undetermined 
cirrhosis in this study might have alcoholic cirrhosis, but might have been misclassified as 
those with non-alcoholic cirrhosis. This can be speculated based on the similarity of the 
aforementioned patient characteristics. This study also utilized the CirCom score as an 
indicator of cirrhosis-specific comorbidity burden, as compared to the more generic Charlson 
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Comorbidity Index. Jepsen et al52 identified the comorbidities that impact survival in patients 
with liver cirrhosis. Using a comorbidity score specific to cirrhosis would help understand the 
burden in these patients much better than using a generic comorbidity index. Thus, the 
current study tried to replicate this score in the study population being assessed to understand 
their comorbidity burden. The original study developing the CirCom looked back 5 years 
from first cirrhosis diagnosis to identify comorbidities, whereas our study had a variable 
period before the index diagnosis as a result of EMR health system entry. Also, this study 
used ICD-9-CM codes as compared to ICD-10 codes that were used in the original study, and 
the definition of ‘active’ comorbidity as described in the present methods differed from that 
of the original study. Though there were methodological variations, the distribution of 
CirCom score observed was found to be similar to the original study.52  Approximately 76% 
of the present sample was classified with CirCom score 0 (indicating no comorbidities), and 
only 0.09% classified with CirCom score 5+1 (indicating high comorbidity burden). Current 
study found a similar distribution trend as observed in the original study; as the score 
increased from 0 to 5+1, the percentage of sample classified under each score decreased with 
increasing severity. Based on the methodology used for the CirCom distribution it can be said 
that this sample had a relatively low comorbidity burden, however an unequal time inclusion 
period for comorbidities for each patient may have introduced some variation into the 
distribution, namely a lower rate of comorbidity than the actual prevalence.  
The MELD/MELDNa score is an indicator of disease severity and is used to prioritize 
patients for liver transplant. It is calculated based on the laboratory testing for serum 
creatinine, bilirubin, INR and sodium (for MELDNa only) which are not more than 48 hours 
old.17 In this study, a wider time frame was utilized, ranging from 3 months prior to 3 months 
post the cirrhosis/complication index date. This time frame was used to cast a wider net to 
capture the severity of the patient using the retrospective design, as well as potential delays in 
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laboratory tests in the outpatient setting. Though such a wide time frame was used, 
MELD/MELDNa score could not be calculated for all the patients, with 20.10% and 32.46% 
having data thereby making it difficult to calculate MELD and MELDNa respectively. This 
could be potentially explained by several factors: (i) non-entry of values in the EMR, (ii) lab 
test not ordered/performed, and (iii) the retrospective nature of study with no access to paper 
medical charts.  
Non-entry of lab values in the EMR for either or all the tests makes it impossible to calculate 
the score as it is dependent on complete values. Though the records were identified based on 
primary and secondary diagnosis for cirrhosis, there might have been an error in ordering lab 
tests to calculate MELD/MELDNa. However, the error rate associated can be expected to be 
low as a primary care physician or specialist would order these tests based on clinical 
experience. Still, there is a chance that the necessary lab values were not ordered as a deficit 
in good clinical care. It should be noted that the use of MELDNa was approved in January 
2016, and thus not all physicians would have specifically recommended a test for serum 
sodium as the study used EMR data from 2009-2014, leading to a MELDNa that could not be 
calculated. However, as serum sodium is part of a basic metabolic panel commonly ordered 
as a part of general clinical care, this cause would be less likely. Finally, records were 
identified retrospectively using EMR, there is a possibility that the lab values obtained were 
entered in paper medical charts for the patients but not in the EMR. The use of EMR within 
the UPMC network is standard, but the degree to which supplemental paper is used in 
individual offices is unknown. 
The second study objective was to assess the change in disease severity via the MELDNa 
from index date of the cirrhosis to the index date of each complication. In cirrhosis, liver 
function is progressively affected due to disease pathophysiology. This affects the normal 
functioning leading to elevated levels of creatinine, bilirubin, sodium and delayed clotting 
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time, all of which are assessed with the MELDNa. A change in MELDNa score from 
cirrhosis to complication index date was assessed to understand the change in severity and 
extent of worsening of the disease over time. As a 3-month pre/post window from index date 
of cirrhosis and complication was used, only those complications with an index date any time 
6 months after the cirrhosis index were used to measure the change. The analysis showed that 
there was a statistically significant increase in the severity from cirrhosis index to each of the 
complication. The significant increase in severity indicates that severity can increase even 
over a short period (6 months). As more complications develop, the increase in severity, 
suggests that patients with cirrhosis are at an increased risk of mortality, as a higher severity 
score corresponds with higher 3-month mortality and need for liver transplant.11,15 An 
increase in MELDNa score as complications develop was seen, helping to verify the use of 
this scoring system as a marker of disease severity. 
The third study objective was to measure office-based, hospital observation, inpatient and 
emergency utilization for the complications. Patients who had at least 365 days of data 
available post-index and more than one visit were included and visits in a 1-year period from 
index of complication as well as visits irrespective of follow-up period post-index was 
measured. Office-based visits could be enumerated for ascites and HE only. Office visits for 
patients with SBP could not be enumerated as these patients are generally seen in an inpatient 
facility, as they are primarily diagnosed, managed and treated in such setting. For both 
patients with ascites and HE, there was no significant difference in office-based utilization 
between the three groups (alcoholic, non-alcoholic, undetermined) for both follow-up 
periods. Based on the results, the underlying diagnosis may not necessarily impact the 
severity of complication and eventually office-based utilization. Ascites patients had more 
number of visits as compared to HE patients. This may have been observed as patients with 
ascites might need paracentesis and more chronic care. However, mean office-based 
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utilization between patients with ascites and HE did not significantly vary when compared 
over 1-year as well as overall follow-up. Both the conditions require medical intervention due 
to their complexity. Based on the results, it can be said that the burden of office-based visits 
is not significantly different between patients with ascites and HE. Hospital observation and 
emergency visits was observed in <5% of both ascites and HE patients for both the follow-up 
period. Though, a small number of patients were analyzed, ascites patients had higher mean 
emergency visits as compared to HE patients. Ascites patients may experience dyspnea and 
abdominal pain due to the distension around the abdominal area and might require emergent 
care for these conditions. HE patients had slightly more hospital observations as compared to 
ascites. HE is episodic in nature and may require visits to the hospital so that the episodes are 
managed effectively.  Similarly, inpatient visits did not significantly differ amongst the 
diagnosis groups in patients with ascites for both 1-year and overall follow-up period. 
However, in patients with HE, a significant difference was observed on the Kruskal-Wallis 
test (median/mean-rank) but not the ANOVA (mean visits) when comparing visits in 1-year 
follow-up. Kruskal-Wallis test requires the distribution of dependent variable across 
independent groups to have a similar shape to compare medians. The underlying distribution 
of inpatient visits was not similar across the three groups; thus, it can be said that the mean 
rank visit score differed but not the median visits. When comparing inpatient visits in HE 
irrespective of follow-up, no significant difference was observed. For a 1-year follow-up, 
ascites patients had significantly more inpatient visits than HE patients. This can be expected 
as ascites patients may need inpatient services for the management of co-existing 
complications such as SBP. No significant difference was observed in inpatient visits when 
follow-up irrespective of time was considered. For SBP, 23.48% and 31.5% of patients had 
inpatient visits in 1-year and overall follow-up, respectively. Differences across diagnosis 
groups was not assessed due to the relatively small sample size and none to negligent office-
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based, hospital observation and emergency visits were observed. In general, comorbidity 
burden may affect utilization patterns. However, 80% of our sample had low comorbidity 
based on the CirCom score and thus the observed utilization patterns might not have been 
influenced by the comorbid conditions. 
The fourth and main objective of the study was to measure concordance with quality care 
parameters and to assess patient- and physician- factors that influence concordance with these 
quality care parameters. This question was divided into three parts: (i) concordance with 
prescribing recommended medications for ascites, HE and SBP; (ii) concordance with 
selected quality care parameters discussed in Table 6; and (iii) assessment of patient- and 
physician-related factors that influence concordance with prescription of recommended 
medications for ascites and HE. The timeline for assessing concordance to guideline varied 
based on the QI. For QI 1 and 2, the concordance was based on MELD and MELDNa score 
that could be reported at the complication index based on the 3-month pre/post inclusion 
criteria for the contributing test values. QI 3 which assessed reporting of weight, the 
concordance was based on the date of cirrhosis visit. QI 4 looked at follow-up visit with 
gastroenterologist, and visits following cirrhosis index were assessed. QI 5 to 9 which 
focused on prescriptions used a 30-day window from complication index as was used by 
Kanwal et al.  
For ascites management, outpatient prescribing of a combination of spironolactone and 
furosemide or spironolactone alone is recommended as a first line therapy by AASLD, with a 
recommended starting dose of 100 mg and 40 mg daily of spironolactone and furosemide 
combination respectively, or 100 mg daily of spironolactone alone.27 The study results 
revealed that only 58% of patients received either of the recommended diuretic therapies 
within 30-days of outpatient visit. Of these patients 23% received spironolactone alone with a 
mean (SD) daily dose of 85.27 mg (50.49) and 77% received combination therapy with a 
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mean (SD) dosing ratio for spironolactone: furosemide of 90.75 (48.49) mg to 43.91 (30.59) 
mg. Forty-two percent of patients did not receive or have any record of receiving any of the 
assessed diuretic therapies within 30-days of outpatient visit.  
The mean dose and mean dosing ratio for spironolactone and spironolactone: furosemide 
combination respectively deviated slightly from the recommended doses. This may be 
explained by the clinical judgment of the physician, who might have preferred a lower or 
higher dose than recommended to be prescribed based on patient clinical factors such as 
blood pressure, renal function or potassium abnormalities. It also may reflect a lower starting 
dose and lack of upward titration over time. Additionally, as patients were identified with 
ascites between 2009-2014 based on availability of the data, it is possible that the patients 
might have had ascites before 2009 which is not captured and physician would have 
prescribed (or adjusted) a lower or higher dose based on the prior knowledge of the response 
and need of the patient for the dose of therapy.  
Overall, the concordance with prescribing outpatient diuretic medications was lower 
compared to earlier studies. Studies by Kanwal et al44 and Le et al45 assessing quality of care 
in VA (n=774) and tertiary care hospital (n=302)  population showed that concordance with 
diuretic therapy was 82.8% and 86% respectively, broadly higher as compared to our study. 
In our study, it is possible that the patients may have received the recommended therapy 
more than 30-days after outpatient visit. In addition, it is possible that the prescription details 
were not recorded in the EMR. Lack of appropriate diuretic therapy can have severe clinical 
implications as they help in reducing the volume of ascitic fluid. Ascites itself is associated 
with 1- and 5-year mortality of 15% and 44%, respectively; and SBP is further associated 
with in-hospital 20% mortality.27,30 
ARB, ACEI, NSAID and BB were prescribed to 2.02%, 2.91%, 7.29% and 25.78% of the 
patients with ascites in the study. These medications are to be used with caution in patients 
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with ascites, utilizing clinical judgment and consideration of comorbid conditions which may 
warrant prescription. PH is a common cause leading to ascites and is managed by BB, thus 
about a quarter of patients might have had a prescription for managing their PH.58-60 NSAID, 
ARB, and ACEI interfere with renal perfusion and lead to reduce sodium excretion (due to 
NSAID) and development of rapid renal failure (NSAID, ARB, and ACEI).27 Poor kidney 
function will eventually lead to salt and water accumulation worsening the ascites and/or 
progress to HRS which is associated with median survival time of 2 weeks and 6 months for 
HRS type 1 and HRS type 2 respectively.61 This analysis is unable to state whether use of 
these medications was completely clinically appropriate.  
The AASLD mentions that use of PPI is associated with increased risk in patients with 
cirrhosis and ascites. Though, there is no guideline around it, we assessed patients with 
ascites with a prescription for PPI. Of the eligible 892 patients, 234 (26.23%) of the patients 
had a PPI prescription. Though AASLD specifies restricting the use of PPI (citing only one 
study) to only those conditions where needed, controversy exists around the association 
between PPI use and risk of SBP.27,62 Multiple studies using retrospective, prospective 
designs, systematic reviews and meta-analyses have shown conflicting results (positive as 
well as negative association) and there is no conclusive evidence or consensus confirming a 
causality to support a guideline on using caution while prescribing ascites patients with PPI 
to reduce SBP risk.62-81 Though our study found over a quarter patients with ascites having a 
prescription for PPI, it cannot be strongly said that deviation from quality care was observed, 
due to the conflicting evidence. PPI may have been prescribed to these patients for other 
existing conditions which were not analyzed as a part of this study.  
Recommended therapies for HE were prescribed to 50% of patients, which was similarly 
poor to prescribing for ascites. A total of 66% of those receiving recommended therapy were 
prescribed lactulose; whereas the remaining 34% were prescribed lactulose and rifaximin in 
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combination. Lactulose and lactulose with rifaximin as an add-on has been recommended by 
the AASLD guidelines for HE management based on meta-analysis and clinical trial 
data.31,82-86 HE is characterized by cognitive and motor dysfunctionality and considering that 
AASLD recommends the aforementioned medications, the observed poor concordance is of 
concern, particularly as the associated 1-year mortality rate is up to 64%.3 It is to be noted 
that AASLD guidelines are mostly focused on management of OHE, and not CHE or MHE. 
The guidelines recommend CHE/MHE treatment on a case-by-case basis, using the same 
treatments as for OHE. We could not ascertain if the patient had OHE or CHE/MHE which 
might have contributed to the observed concordance, as patients with MHE/CHE might not 
have received the treatment. In addition, hypnotics, antidepressants, benzodiazepines and 
opioids were prescribed to 1.98%, 5.28%, 7.43% and 20.46% of the eligible patients for HE 
quality care parameter. Though not specifically mentioned in the AASLD guidelines, 
literature supports avoidance of these medications in HE as they can cause cognitive 
dysfunction or even worsen the condition and thus good clinical judgment would suggest that 
these medications should be prescribed with care.53  
Long-term outpatient antibiotics within 30-days of hospital discharge post-SBP is a 
recommended secondary prophylactic strategy by Kanwal et al37 and AASLD (with no 
specific mention of 30-day window). Secondary prophylaxis was prescribed to 54% of 
patients, which was overall less than optimal, but lies between HE (lower) and ascites 
(higher) concordance. Majority of patients (57.89%) were prescribed varied doses of 
ciprofloxacin (with 57.57% receiving a 750 mg/weekly dose); followed by varied doses of 
sulfamethoxazole/trimethoprim (35.08%). Thevenot et al46 in their study assessing 
prescribing for GI bleeding and SBP, found that 94.8% of the practitioners prescribed 
secondary prophylaxis over life (defined as resolution of ascites or until transplantation), a 
significantly higher concordance as compared to our study. Le et al45 assessing quality care 
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and its association with outcomes in hospitalized patients found 70% concordance rate for the 
patients eligible for secondary prophylaxis. Kanwal et al44 in their study assessing quality of 
care for ascites in VA population found that of the 30 eligible patients only 30% received 
secondary prophylaxis. Overall, this study found less than desirable concordance to the 
quality care parameter, lower than studies by Thevenot et al46, and Le et al45, but 
comparatively better than Kanwal et al.44 Recurrence rate of SBP is approximately 40-70% 
within the first year of successfully clearing an episode of SBP using antibiotic therapy.29 The 
less than desirable concordance observed is a cause of concern as patients surviving SBP 
hospitalization have an associated 1-year and 5-year mortality of approximately 70% and 
80%.29  
When identifying patients eligible for this SBP indicator, up to ten ICD-9-CM codes 
including primary diagnoses for that hospitalization were used to identify SBP patients. There 
is a possibility that patients who did not present with SBP as a primary condition for 
hospitalization did not receive the recommended antibiotic prophylaxis. Due to retrospective 
nature of this study it is difficult to assess if the non-prescribing is attributable to SBP not 
being the primary condition for hospitalization. Irrespective of SBP being primary or non-
primary reason for hospitalization it would be expected that patients receive outpatient 
antibiotic prophylaxis post discharge to avoid recurrence of the condition. In general, 
concordance with outpatient prescription was observed to be less than desirable which can 
eventually influence healthcare utilization patterns, clinical outcomes, and mortality. Though, 
association between concordance to medication and utilization patterns was not assessed, the 
observed concordance might affect utilization in a general sense. 
MELD/MELDNa scores could be comparatively better calculated at complication index as 
compared to cirrhosis index. Amongst the three complications, MELD/MELDNa score at 
complication index was calculated for nearly all the patients with SBP. HE had the least 
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number of patients for whom the score could be calculated. A window of 3-month pre/post 
complication index was used to identify test values used to calculate MELD/MELDNa 
scores. Though such a broad window was used, the severity scores could only be calculated 
for ≤ 90% for the complication samples (except SBP). This is less than desirable as MELD/ 
MELDNa are used as a severity measure to prioritize transplant patients. The absence of lab 
values used to calculate MELD/MELDNa at complication index can be explained by similar 
reasons discussed earlier for MELD/MELDNa scores at cirrhosis index. The observed 
concordance to MELD/MELDNa was significantly better than the prescription patterns. 
Higher concordance to MELD/MELDNa might have been observed as severity 
documentation gives an idea to the physician about the clinical condition/progression of a 
patient and is more information-gathering than interventional; whereas, the treatment 
modality used might vary based on the patient and the physician judgement. This study 
analyzed outpatient prescribing patterns, thus we might have observed lower rates of 
concordance as compared to MELD/MELDNa documentation (where a broad inclusion 
window was used for the score calculation). 
Measures for weight and appointments with gastroenterology were included as measures of 
quality care based on good clinical practice, as opposed to specific guideline 
recommendations. Weight loss can be due to multiple reasons, and is common symptom of 
cirrhosis progression. In addition, weight gain (due to fluid accumulation) can be used as a 
surrogate measure for monitoring the status of ascites. Of all the cirrhosis-specific office-
based outpatient visits, weight was recorded in 79.69% of total visits. Gastroenterologists are 
specialists in cirrhosis-related care and thus it is important that patients are seen by such 
specialists to receive best care for management of the condition. Eighty-three percent of 
patients with cirrhosis were seen by a gastroenterologist for at least one of the follow-up 
office-based outpatient visit recorded in the EMR. For the remaining 17% who did not have a 
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record of follow-up visit with gastroenterologist, reasons for no follow-up could not be 
assessed due to the nature of the study. Also, depending on the severity of the patient, the 
patient might have been referred to an inpatient setting, this again was not confirmed as a part 
of the analysis. 
In patients with ascites with low ascitic fluid protein, along with impaired renal function or 
liver failure, AASLD27 and Kanwal et al37 recommend long-term use of norfloxacin or 
trimethoprim/sulfamethoxazole as a primary prophylactic measure to reduce bacterial 
infection and mortality. In this study, 33 patients were identified as eligible for this therapy, 
of these only 22 (60.61%) received it within 30-days of outpatient visit. Eligible patients 
were identified based on diagnosis of ascites at index and the necessary lab values. However, 
Child-Pugh score could not be included in the decision process as there was no information 
available in the EMR for grade of hepatic encephalopathy, which is necessary to calculate the 
score. This study found comparatively better rates of concordance with this quality parameter 
as compared to those by Kanwal et al44 (22.2%) and Ghaoui et al40,42 (33.3%) but lower than 
those by Thevenot et al46 (72.3%) and Le et al45 Primary prophylaxis is recommended by 
AASLD as a measure to reduce risk of SBP and mortality.27 
Logistic regression models assessing factors associated with concordance with guidelines had 
limited predictability. BMI and physician type, for both ascites and HE model were the only 
variables that were associated with concordance with recommended therapy for ascites and 
HE. Among the different studies that assessed quality of care in ascites, HE and SBP, the 
study by Kanwal et al44 was the only one which studied association of patient- and physician- 
factors associated with guideline/QI concordance.  The study assessed factors associated with 
concordance with eight different quality indicators, whereas this study looked at association 
of these factors only with one quality parameter (i.e. receiving outpatient therapy for ascites 
and HE).  
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In our ascites model, overweight patients had significantly lower odds of receiving diuretic 
therapy. Though not statistically significant, obese patients also had lower odds of receiving 
diuretic therapy. The negative association of being overweight and concordance with diuretic 
therapy is a surprising association and is unknown why a higher BMI would impact diuretic 
prescription. Physicians categorized as ‘others’ had significantly lower odds to prescribe 
diuretic therapy as compared to primary care physicians. This would be expected as their 
knowledge pertaining to ascites care would be anticipated to be more limited than a primary 
care physician or gastroenterology specialist. Surprisingly, though not significantly 
associated, gastroenterologists were less likely to prescribe diuretic therapy as compared to 
primary care physicians.  
The logistic model for HE showed that obese patients and physicians categorized as ‘others’ 
were significantly less likely to receive and prescribe lactulose or lactulose and rifaximin, 
respectively. The association between obesity and lower odds of receiving HE therapy may 
be attributable to lack of other factors that could not be included in the model due to 
availability in the EMR and small sample size. Similar to the ascites model, physicians 
categorized as ‘others’ had significantly lower odds to prescribe (adhere to) HE therapy as 
compared to primary care physicians. This would be expected as their knowledge pertaining 
to HE care would be anticipated to be more limited than a primary care physician or 
gastroenterology specialist. Though not significantly associated, gastroenterologists were less 
likely to prescribe HE treatment as compared to primary care physicians. In this scenario, it 
can also be said that this may be observed as gastroenterologists may have considered a 
different treatment modality as these patients may not necessarily have new-onset hepatic 
encephalopathy, or have MHE/CHE and thus have other care needs.  
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Limitations 
Study limitations must be considered when interpreting the results. The study data was 
obtained from EMR of an academic-based network of hospitals serving southwestern 
Pennsylvania, thus the study results may not be generalizable to the entire US population. 
Second, analysis was conducted using EMR data which might have limited quality due to 
recorder bias, incomplete data, coding errors. Data quality due to missing data was accounted 
for by using complete case analysis, however it might bias some of the results. Third, limited 
sample size was obtained for ascites, HE and specifically for SBP. Thus, a multivariable 
logistic model could not be developed for SBP. Fourth, in general, both the logistic models 
for ascites and HE did not reveal much about potential associations between the predictors 
and outcome. This can be attributable to missing variables in the EMR that could have better 
explained the outcome. Fifth, ascites, HE and SBP can be managed both on an outpatient and 
inpatient basis and the study looked at quality of care on an outpatient basis only. Inpatient 
care might have been provided to these patients instead of outpatient care based on clinical 
need. This however could not be ascertained and confirmed due to limited access to inpatient 
data. Sixth, reasons for observed concordance to care could not be identified and reported due 
to lack of access to patient charts. Finally, this study used a cross-sectional assessment of 
quality of care and quality care over time could not be assessed which would have provided a 
better estimation. 
 
Study implications 
The study findings have various implications for provision of quality care in a clinical setting. 
Based on study results, there may be opportunities to improve clinical care for patients with 
cirrhosis and complications. First, the study described the demographics and clinical 
characteristics of the population served by the network of hospitals providing the EMR. The 
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study provides a snapshot of the patient demographic and clinical characteristics that are 
prevalent in this population. This study used the CirCom score to identify comorbidity 
burden in these patients. This scoring can help physicians understand the burden of 
comorbidities in the liver cirrhosis population they serve as well as use it as a tool for future 
patients. Second, the study found that there was less than desirable concordance with clinical 
care guidelines. EMR are rich sources of data that can be used for providing efficient and 
quality care. Use of EMR for assessing patient history and providing the necessary care is 
important to achieve better outcomes in patients. In our study, we observed that there was 
poor documentation of lab values used to calculate the MELDNa score which is an important 
indicator of disease severity and indicator of prioritizing liver transplantation. Though, these 
values may have been documented on medical charts, it is important that they be documented 
in the EMR for understanding the condition of the patient and accordingly provide necessary 
care. In general, documentation of patient data in EMR can provide deep insight into 
patient’s condition and be used to provide patient-centered care based on evidence or 
established quality parameters.   
Lastly, evidence-based guidelines/quality parameters are increasingly used to guide patient 
care. The study assessed concordance with some of these and found that they might not be 
implemented in real-world clinical practice. Study results can be used by physicians to assess 
current practice patterns and accordingly modify them to provide more evidence-based care 
and eventually achieve better patient outcomes. The study results highlight need for protocol 
driven treatment, opportunities for physician education, and promoting coordinated team-
based care to ensure delivery of quality care. Such approaches can be used effectively to 
create a systematic health system that provides the necessary evidence-based care using a 
structured established process.  
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Future directions 
Based on the study results, less than desirable concordance with quality care parameters was 
observed, which may lead to poor quality of care. This study also tried to assess patient- and 
physician- factors associated with concordance with quality care but revealed limited results. 
Further research can focus on assessing patient- and physician- factors that govern quality 
care which did not yield rich results in this study. Our study mainly focused on outpatient 
care due to limited access to inpatient records. Further studies can assess concordance with 
quality parameters in an inpatient and outpatient setting and identify factors associated with 
quality care. Our study did not assess concordance with quality care and impact on outcomes 
which can be assessed by future studies. Liver cirrhosis and the associated complications 
involve coordinated care due to the complex nature of the disease. Studies using a 
prospective design can be used to assess impact of coordinated care on concordance with 
quality care and eventually outcomes.  
 
Conclusion 
Chronic liver diseases are the 12th leading cause of mortality in the United States.19 Liver 
cirrhosis and the associated complications have no cure and are solely based on management 
strategies to slow the disease progression and improve survival. Our study looked at 
concordance with various quality care parameters and patient-, and physician- factors 
associated with concordance with certain parameters. Overall, we conclude that concordance 
with quality care was less than desirable. Study results assessing patient- and physician- 
factors associated concordance revealed limited information. The study results highlight lack 
of concordance with quality parameters and hence thereof improving care standards to 
provide quality care.  
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